








SHEA/IDSA/APIC Practice Recommendation

Strategies to prevent surgical site infections in acute-care hospitals: 2022 Update

Michael S. Calderwood MD, MPH^{1,a}, Deverick J. Anderson MD, MPH^{2,a} , Dale W. Bratzler DO, MPH³, E. Patchen Dellinger MD⁴ , Sylvia Garcia-Houchins RN, MBA, CIC⁵, Lisa L. Maragakis MD, MPH⁶ , Ann-Christine Nyquist MD, MSPH⁷, Kiran M. Perkins MD, MPH⁸, Michael Anne Preas RN, MS, CIC⁹ , Lisa Saiman MD, MPH¹⁰ , Joshua K. Schaffzin MD, PhD¹¹ , Marin Schweizer PhD¹² , Deborah S. Yokoe MD, MPH¹³ and Keith S. Kaye MD, MPH^{14,b}

¹Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States, ²Duke Center for Antimicrobial Stewardship and Infection Prevention, Duke University School of Medicine, Durham, North Carolina, United States, ³University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States, ⁴University of Washington Medical Center, Seattle, Washington, United States, ⁵The Joint Commission, Oakbrook Terrace, Illinois, United States, ⁶Johns Hopkins School of Medicine, Baltimore, Maryland, United States, ⁷Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado, United States, ⁸Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, United States, ⁹University of Maryland Medical System, Baltimore, Maryland, United States, ¹⁰Columbia University Irving Medical Center and NewYork–Presbyterian Hospital, New York, New York, United States, ¹¹Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, Ontario, Canada, ¹²Center for Access and Delivery Research and Evaluation, Iowa City VA Health Care System, University of Iowa, Iowa City, Iowa, ¹³University of California-San Francisco, San Francisco, California, United States and ¹⁴Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States

Abstract and purpose

The intent of this document is to highlight practical recommendations in a concise format designed to assist acute-care hospitals in implementing and prioritizing their surgical site infection (SSI) prevention efforts. This document updates the *Strategies to Prevent Surgical Site Infections in Acute Care Hospitals* published in 2014.¹ This expert guidance document is sponsored by the Society for Healthcare Epidemiology of America (SHEA). It is the product of a collaborative effort led by SHEA, the Infectious Diseases Society of America (IDSA), the Association for Professionals in Infection Control and Epidemiology (APIC), the American Hospital Association (AHA), and The Joint Commission, with major contributions from representatives of a number of organizations and societies with content expertise.

(Received 20 March 2023; accepted 21 March 2023; electronically published 4 May 2023)

Summary of major changes

This section lists major changes from the *Strategies to Prevent Surgical Site Infections in Acute Care Hospitals: 2014 Update*,¹ including recommendations that have been added, removed, or altered. Recommendations are categorized as essential practices that should be adopted by all acute-care hospitals (in 2014 these were “basic practices,” renamed to highlight their importance as a foundation for hospitals’ healthcare-associated infection (HAI) prevention programs) or additional approaches that can be considered for use in locations and/or populations within hospitals when SSIs are not controlled after implementation of essential practices (in 2014 these were called “special approaches”). See Table 1 for

a complete summary of recommendations contained in this document.

Essential practices

- Modified recommendation to administer prophylaxis according to evidence-based standards and guidelines to emphasize that antimicrobial prophylaxis should be discontinued at the time of surgical closure in the operating room.
- The use of parenteral and oral antibiotics prior to elective colorectal surgery is now considered an essential practice. This recommendation was included in the 2014 document but was a sub-bullet recommendation. This recommendation was elevated to its own recommendation for increased emphasis.
- Reclassified decolonization of surgical patients with an anti-staphylococcal agent for cardiothoracic and orthopedic procedures from an Additional Approach to an Essential Practice.
- The use of vaginal preparation with an antiseptic solution prior to cesarean delivery and hysterectomy was added as an essential practice.

Author for correspondence: Michael S. Calderwood, MD, MPH, michael.s.calderwood@hitchcock.org

^aAuthors of equal contribution.

^bSenior author.

Cite this article: Calderwood MS, Anderson DJ, Bratzler DW, *et al.* (2023). Strategies to prevent surgical site infections in acute-care hospitals: 2022 Update. *Infection Control & Hospital Epidemiology*, 44: 695–720, doi: 10.1017/ice.2023.67

© The Author(s), 2023. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.

Table 1. Summary of Recommendations to Prevent Surgical Site Infections (SSIs)

Essential practices
1. Administer antimicrobial prophylaxis according to evidence-based standards and guidelines. ^{73,75} (Quality of evidence: HIGH)
2. Use a combination of parenteral and oral antimicrobial prophylaxis prior to elective colorectal surgery to reduce the risk of SSI. ^{115,116} (Quality of evidence: HIGH)
3. Decolonize surgical patients with an anti-staphylococcal agent in the preoperative setting for orthopedic and cardiothoracic procedures. (Quality of evidence: HIGH) Decolonize surgical patients in other procedures at high risk of staphylococcal SSI, such as those involving prosthetic material. (Quality of evidence: LOW)
4. Use antiseptic-containing preoperative vaginal preparation agents for patients undergoing cesarean delivery or hysterectomy. (Quality of evidence: MODERATE)
5. Do not remove hair at the operative site unless the presence of hair will interfere with the surgical procedure. ^{4,119} (Quality of evidence: MODERATE)
6. Use alcohol-containing preoperative skin preparatory agents in combination with an antiseptic. (Quality of evidence: HIGH)
7. For procedures not requiring hypothermia, maintain normothermia (temperature > 35.5°C) during the perioperative period. (Quality of evidence: HIGH)
8. Use impervious plastic wound protectors for gastrointestinal and biliary tract surgery. (Quality of evidence: HIGH)
9. Perform intraoperative antiseptic wound lavage. ¹⁷¹ (Quality of evidence: MODERATE)
10. Control blood-glucose level during the immediate postoperative period for all patients. ⁹⁴ (Quality of evidence: HIGH)
11. Use a checklist and/or bundle to ensure compliance with best practices to improve surgical patient safety. (Quality of evidence: HIGH)
12. Perform surveillance for SSI. (Quality of evidence: MODERATE)
13. Increase the efficiency of surveillance by utilizing automated data. (Quality of evidence: MODERATE)
14. Provide ongoing SSI rate feedback to surgical and perioperative personnel and leadership. (Quality of evidence: MODERATE).
15. Measure and provide feedback to HCP regarding rates of compliance with process measures. ⁹⁴ (Quality of evidence: LOW)
16. Educate surgeons and perioperative personnel about SSI prevention measures. (Quality of evidence: LOW)
17. Educate patients and their families about SSI prevention as appropriate. (Quality of evidence: LOW)
18. Implement policies and practices to reduce the risk of SSI for patients that align with applicable evidence-based standards, rules and regulations, and medical device manufacturer instructions for use. ^{4,94} (Quality of evidence: MODERATE)
19. Observe and review operating room personnel and the environment of care in the operating room and in central sterile reprocessing. (Quality of evidence: LOW)
Additional approaches
1. Perform an SSI risk assessment. (Quality of evidence: LOW)
2. Consider use of negative pressure dressings in patients who may benefit. (Quality of evidence: MODERATE)
3. Observe and review practices in the preoperative clinic, postanesthesia care unit, surgical intensive care unit and/or surgical ward. (Quality of evidence: MODERATE)
4. Use antiseptic-impregnated sutures as a strategy to prevent SSI. (Quality of evidence: MODERATE)
Approaches that should not be considered a routine part of SSI prevention
1. Do not routinely use vancomycin for antimicrobial prophylaxis. ⁷³ (Quality of evidence: MODERATE)
2. Do not routinely delay surgery to provide parenteral nutrition. (Quality of evidence: HIGH)
3. Do not routinely use antiseptic drapes as a strategy to prevent SSI. (Quality of evidence: HIGH)
Unresolved issues
1. Optimize tissue oxygenation at the incision site
2. Preoperative intranasal and pharyngeal CHG treatment for patients undergoing cardiothoracic procedures
3. Use of gentamicin-collagen sponges
4. Use of antimicrobial powder
5. Use of surgical attire

- Reclassified intraoperative antiseptic wound lavage from an Additional Approach to an Essential Practice. However, this approach should only be used when sterility of the antiseptic can be ensured and maintained.
- Control of blood-glucose levels during the immediate postoperative period for all patients was modified (1) to emphasize the importance of this intervention regardless of a known diagnosis

- of diabetes mellitus, (2) to elevate the evidence level to “high” for all procedures, and (3) to lower the target glucose level from <180 mg/dL to 110–150 mg/dL.
- Reclassified use of bundles to promote adherence with best practices from Unresolved to an Essential Practice. Discussion of the use of checklists and bundles was combined for this recommendation.

- Reclassified observe and review operating room personnel and the environment of care in the operating room and central sterile reprocessing from an Additional Approach to an Essential Practice.

Additional approaches

- Reclassified the recommendation to perform an SSI risk assessment from an Essential Practice to an Additional Approach.
- The use of negative pressure dressings was added as an Additional Practice. To date, available evidence suggests that this strategy is most likely effective in specific procedures (eg, abdominal procedures) and/or specific patients (eg, increased body mass index).
- Reclassified the use of antiseptic-impregnated sutures from Not Recommended to Additional Approaches.

Not recommended

- Expanded discussion on the recommendation against the routine use of vancomycin for antimicrobial prophylaxis.

Unresolved issues

- Reclassified the use of supplemental oxygen for patients requiring mechanical ventilation from an Essential Practice to Unresolved.
- Added discussion on the use of antimicrobial powder.
- Added discussion on the use of surgical attire as a strategy to prevent SSI.

Intended Use

This document was developed following the process outlined in the *Handbook for SHEA-Sponsored Guidelines and Expert Guidance Documents*.² No guideline or expert guidance document can anticipate all clinical situations, and this document is not meant to be a substitute for individual clinical judgment by qualified professionals.

This document is based on a synthesis of evidence, theoretical rationale, current practices, practical considerations, writing-group consensus, and consideration of potential harm, when applicable. A summary list of recommendations is provided along with the relevant rationale in Table 1.

Methods

SHEA recruited 3 subject-matter experts in the prevention of SSI to lead the panel of members representing the Compendium partnering organizations—SHEA, IDSA, APIC, AHA, and The Joint Commission, as well as representation by the Centers for Disease Control and Prevention (CDC).

SHEA utilized a consultant medical librarian, who developed a comprehensive search strategy for PubMed and Embase (January 2012–July 2019, updated to August 2021). Article abstracts were reviewed by panel members. Each abstract was reviewed by at least 2 reviewers using the abstract management software Covidence (Melbourne, Australia), and selected abstracts were reviewed as full text. In July 2021, the Compendium Lead Authors group voted to update the literature findings, and the librarian re-ran the search to update it to August 2021. Panel members reviewed the search yield via Covidence and incorporated relevant references.

Table 2. Quality of Evidence^a

HIGH	Highly confident that the true effect lies close to that of the estimated size and direction of the effect, for example, when there are a wide range of studies with no major limitations, there is little variation between studies, and the summary estimate has a narrow confidence interval.
MODERATE	The true effect is likely to be close to the estimated size and direction of the effect, but there is a possibility that it is substantially different, for example, when there are only a few studies and some have limitations but not major flaws, there is some variation between studies, or the confidence interval of the summary estimate is wide.
LOW	The true effect may be substantially different from the estimated size and direction of the effect, for example, when supporting studies have major flaws, there is important variation between studies, the confidence interval of the summary estimate is very wide, or there are no rigorous studies.

^aBased on the CDC Healthcare Infection Control Practices Advisory Committee (HICPAC) “Update to the Centers for Disease Control and Prevention and the Healthcare Infection Control Practices Advisory Committee Recommendations Categorization Scheme for Infection Control and Prevention Guideline Recommendations” (October 2019), the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE),³³⁹ and the Canadian Task Force on Preventive Health Care.³⁴⁰

Recommendations resulting from this literature review process were classified based on the quality of evidence and the balance between desirable and potential for undesirable effects of various interventions (Table 2). Panel members met via video conference to discuss literature findings; recommendations; quality of evidence for these recommendations; and classification as essential practices, additional practices, or unresolved issues. Panel members reviewed and approved the document and its recommendations.

The Compendium Expert Panel, made up of members with broad healthcare epidemiology, surgical, and infection prevention expertise, reviewed the draft manuscript after consensus had been reached by writing-panel members.

Following review and approval by the Expert Panel, the 5 Compendium partners, collaborating professional organizations, and CDC reviewed the document. Prior to dissemination, the guidance document was reviewed and approved by the SHEA Guidelines Committee, the IDSA Practice Standards and Guidelines Committee, AHA, and The Joint Commission, and the Boards of SHEA, IDSA, and APIC.

All panel members complied with the SHEA and IDSA policies on conflict-of-interest disclosure.

Section 1: Rationale and statements of concern

Burden of outcomes associated with SSI

1. Surgical site infections (SSIs) are common complications in acute-care facilities.
 - a. SSIs occur in ~1%–3% of patients undergoing inpatient surgery, depending on the type of operative procedure performed.^{3,4} In total, 21,186 SSIs were reported to the CDC National Healthcare Safety Network (NHSN) in 2021 from a total of 2,759,027 operative procedures.³
 - b. Additional data on ambulatory and outpatient surgeries are needed. Overall, many of these procedures are lower risk by virtue of procedure type and patient selection, and some may involve minimally invasive techniques that have a lower risk of infection.^{5,6} It is important to mention, however, that both

inpatient and ambulatory operating rooms need to adhere to strict infection prevention standards.

- c. SSIs now are one of the most common and most costly HAIs.^{7–11}
2. Up to 60% of SSIs are preventable using evidence-based guidelines.^{12,13}
3. When not prevented, SSIs can result in a significant increase in postoperative hospital days and many also require reoperation, both during the initial surgical admission and during hospital readmission.^{11,14–16}
4. Patients with an SSI have a 2–11 times higher risk of death compared to operative patients without SSI.^{17,18} Also, 77% of deaths in patients with SSI are directly attributable to SSI.¹⁹
5. Attributable costs of SSI vary depending on the type of operative procedure, medical implants, and the type of infecting pathogen.^{16,18,20–27} Overall, it is estimated that the cost of care for patients who develop an SSI is 1.4–3 times higher than for patients who do not develop an SSI.²⁸ Deep-incisional and organ-space SSIs are associated with the highest cost.²⁸ All studies evaluated in a systematic review reported some economic benefit associated with SSI prevention, but there is significant heterogeneity in the literature related to cost accounting.^{29,30} In the United States, SSIs are believed to account for \$3.5 billion to \$10 billion annually in healthcare expenditures.^{31,32}
6. Finally, data reported to the CDC NHSN show that SSIs can be caused by antibiotic-resistant bacteria such as methicillin-resistant *Staphylococcus aureus*, vancomycin-resistant Enterococci, and multidrug-resistant gram-negative bacilli. These infections can be more difficult to manage and can be caused by pathogens that are resistant to standard empiric antibiotics.³³

Risk factors for SSI

1. Numerous risk factors have been described for SSI, including intrinsic factors, patient-specific risk factors, and perioperative factors related to surgical practices (Table 3). Some common patient-specific risk factors include obesity, diabetes, immunosuppressive therapy, malnutrition, and smoking. In pediatrics, premature infants are also at higher risk, especially those undergoing gastrointestinal surgery early in life. Examples of perioperative risk factors include inadequacies in surgical scrub, the antiseptic preparation of the skin, antimicrobial prophylaxis, and duration of surgery.
2. The CDC NHSN-determined risk factors for different procedure categories are incorporated in the calculation of the standardized infection ratio (SIR).³⁴

Section 2: Background on detection of SSI

Surveillance definitions for SSI

1. Surveillance definitions must be established and consistently applied over time to make comparisons within and between institutions meaningful.
 - a. NHSN definitions for SSI are widely used for public reporting, interfacility comparison, and pay-for-performance comparisons,^{35–38} based on selected procedures identified by procedure codes assigned from the *International Classification of Diseases, 10th Revision*

Clinical Modifications/Procedure Coding System (ICD-10-CM/PCS) and/or current procedural terminology (CPT) codes.^{35–37}

- b. Validation of the application of surveillance definitions between data abstractors may be necessary to ensure consistent application.^{41,42}
2. According to widely used CDC NHSN definitions,⁴³ SSIs are classified as follows (Fig. 1):
 - a. Superficial incisional (involving only skin or subcutaneous tissue of the incision)
 - i. Superficial incisional primary (SIP): SSI identified in a primary incision in a patient with 1 or more incisions.
 - ii. Superficial incisional secondary (SIS): SSI identified in the secondary incision in a patient that has had an operation with >1 incision.
 - b. Deep incisional (involving fascia and/or muscular layers)
 - i. Deep-incisional primary (DIP): SSI identified in a primary incision in a patient who has had an operation with 1 or more incisions.
 - ii. Deep-incisional secondary (DIS): SSI identified in a secondary incision in a patient who has had an operation with > 1 incision.
 - c. Organ-space: Involving any part of the body opened or manipulated during the procedure, excluding skin incision, fascia, or muscle layers.

Surveillance methods for SSI and detection of patients

1. The most accurate method of SSI surveillance is the direct method for case finding with daily observation of the surgical site by a physician, advanced practice provider, registered nurse, or infection preventionist starting 24–48 hours postoperatively.^{15,44–46} Although the direct method of case finding has been used as the “gold standard” for some studies, it is rarely used by infection prevention staff due to its high resource utilization requirements and impracticality.
2. The indirect method of case finding is less time-consuming than the direct method; it can be performed using criteria or algorithms applied to electronic records; and it can be performed retrospectively.
 - a. The indirect method of case finding consists of 1 or a combination of the following as appropriate based on inpatient or outpatient surveillance and the setting:
 - i. Review of microbiology reports and patient medical records
 - ii. Surgeon and/or patient surveys by mail, telephone, or web-based application⁴⁷
 - iii. Patient or family interview, particularly when postoperative care is remote and/or follow-up care is being provided by an alternative provider
 - iv. Screening for early or additional postoperative visits, readmission, and/or return to the operating room
 - v. Other information such as coded diagnoses, coded procedures, operative reports, or antimicrobials ordered
 - b. Indirect methods of SSI surveillance have been demonstrated to be reliable (sensitivity, 84%–89%) and specific (specificity, 99.8%) compared to the “gold standard” of direct surveillance.^{48–50} Components of the indirect methods that were associated with highest sensitivities included review of nursing notes, billing codes, and antimicrobials used.

Table 3. Selected Risk Factors for and Recommendations to Prevent Surgical Site Infection (SSI)

Risk Factor	Recommendation	Quality of Evidence
<i>Intrinsic, patient-related (preoperative)</i>		
Unmodifiable		
Age	No formal recommendation: relationship to increased risk of SSI may be secondary to comorbidities or immunosenescence. ^{341–343}	N/A
History of radiation	No formal recommendation. Prior irradiation at the surgical site increases the risk of SSI, likely due to tissue damage and wound ischemia. ¹⁸³	N/A
History of skin and soft-tissue infections	No formal recommendation. History of a prior skin infection may be a marker for inherent differences in host immune function. ³⁴⁴	N/A
Modifiable		
Glucose control	Control serum blood-glucose levels for all surgical patients including patients without diabetes. ³⁴⁵	HIGH
Obesity	Increase dosing of prophylactic antimicrobial agent for morbidly obese patients. ^{73,346}	HIGH
Smoking cessation	Encourage smoking cessation within 30 days of procedure. ^{4,347–351}	HIGH
Immunosuppressive medications	Avoid immune-suppressive medications in perioperative period if possible	LOW
Hypoalbuminemia	No formal recommendation. Though a noted risk factor, ³⁵² do not delay surgery for use of total parenteral nutrition.	N/A
<i>S. aureus</i> nasal colonization	Decolonize patients with nasal mupirocin or povidine-iodine prior to surgery	MODERATE
<i>Preparation of patient</i>		
Hair removal	Do not remove unless hair will interfere with the operation ⁴ ; if hair removal is necessary, remove outside of the operating room by clipping. Do not use razors.	HIGH
Preoperative infections	Identify and treat infections remote to the surgical site (eg, urinary tract infection in the presence of prior to elective surgery. ^{4,353} Do not routinely test or treat for asymptomatic bacteriuria except in urologic procedures. ^{4,353}	MODERATE
<i>Operative characteristics</i>		
Surgical scrub (surgical team members' hands and forearms)	Use appropriate antiseptic agent to perform preoperative surgical scrub. ^{4,354} For most products, scrub the hands and forearms for 2–5 minutes.	MODERATE
Skin preparation	Wash and clean skin around incision site. Use a dual agent skin prep containing alcohol unless contraindications exist. ⁴	HIGH
Antimicrobial prophylaxis	Administer only when indicated. ⁴ Select appropriate agents based on surgical procedure, most common pathogens causing SSI for a specific procedure, and published recommendations. ⁷³ Administer within 1 hour of incision to maximize tissue concentration. ⁷³ Discontinue antimicrobial agents after incisional closure in the operating room. ^a	HIGH
Blood transfusion	Blood transfusions increase the risk of SSI by decreasing macrophage function. Reduce blood loss and need for blood transfusion to greatest extent possible. ^{355–357}	MODERATE
Surgeon skill/technique	Handle tissue carefully and eradicate dead space. ⁴	LOW
Appropriate gloving	All members of the operative team should double glove and change gloves when perforation is noted. ³⁵⁸	LOW
Asepsis	Adhere to standard principles of operating room asepsis. ⁴	LOW
Operative time	No formal recommendation in most recent guidelines; minimize as much as possible without sacrificing surgical technique and aseptic practice.	HIGH
<i>Operating room characteristics</i>		
Ventilation	Follow American Institute of Architects' recommendations for proper air handling in the operating room. ^{4,359}	LOW
Traffic	Minimize operating room traffic. ^{4,207,208}	LOW
Environmental surfaces	Use an Environmental Protection Agency (EPA)-approved hospital disinfectant to clean visibly soiled or contaminated surfaces and equipment in accordance with manufacturer's instructions. ⁴	LOW
Sterilization of surgical equipment	Sterilize all surgical equipment according the device manufacturer's validated parameters: cycle type, time, temperature, pressure, and dry time. Minimize the use of immediate use steam sterilization. ^{4,360}	MODERATE

^aVancomycin and fluoroquinolones can be given 2 hours prior to incision.

- c. Indirect methods for SSI surveillance are less reliable for surveillance of superficial-incisional infections, particularly those occurring after discharge.⁵¹
3. Automated data systems and electronic health records should be used to improve efficiency, improve sensitivity, and broaden SSI surveillance.⁵⁰




Fig. 1. CDC National Healthcare Safety Network (NHSN) classification for surgical site infection. Modified from Horan TC, et al.³⁶² CDC definitions of nosocomial surgical site infections, 1992.

- a. SSI surveillance can be expanded by utilizing hospital databases that include administrative claims data (including diagnosis and procedure codes), antimicrobial days, readmission to the hospital, return to the operating room and/or by implementing a system that imports automated microbiologic culture data, surgical procedure data, and general demographic information into a single surveillance database.^{52–54}
 - b. These methods improve the sensitivity of indirect surveillance for detection of SSI and reduce the effort of the infection preventionist.⁵²
 - c. Medicare claims data can be used to enhance surveillance methods for SSI and to identify hospitals with unusually high or low rates of SSI.^{55,56}
 - d. Administrative data can be used to increase the efficiency of SSI reporting and validation.^{57–59}
 - e. Use of algorithms,⁵⁸ machine learning,⁶⁰ and predictive models may be helpful in surveillance of SSIs.
 - f. Administrative and automated data used for surveillance purposes should be validated to ensure accuracy.
 - g. Electronic health record (EHR) vendors should increase standardization and automated collection of key metrics. The focus should be to reduce data burden on hospital and health-system staff.
4. The proportion of SSIs detected through postdischarge surveillance can vary by surveillance method, operative setting, type of SSI, and surgical procedure.
 - a. The majority of surgical procedures are now outpatient procedures.⁶¹ In addition, length of stay following inpatient procedures has decreased. Surveillance methodologies must take these practice changes into account.
 - b. Superficial incisional SSIs are most commonly detected and managed in the outpatient setting. In contrast, deep-incisional and organ-space infections typically require readmission to the hospital for management.⁵¹
 - c. Surveillance for SSIs in the ambulatory care setting is challenging because patients may not return to the same organization for routine postoperative care⁶² or for management of complications.⁶³
 5. CDC is prescriptive about denominator data collection⁴³; however, it is less prescriptive on how possible cases (numerator data) should be identified for evaluation.
 - a. Differences in case finding methodology may lead to variability in surveillance rates.⁶⁴
 - b. CDC encourages standardization of data sources for more consistent reporting. Both state health departments and the CMS select hospitals for data validation.
 - c. By improving completeness of reporting, the overall institutional SSI rate typically increases.^{65–67} As more data sources are used, the detection of SSIs is likely to increase.⁵²

Section 3: Background on prevention of SSI

Summary of existing guidelines, recommendations, and requirements

A number of guidelines are available on the prevention of SSIs, and our writing panel compared and contrasted some of the differences in developing our current recommendations.⁶⁸ We list some of these guidelines below, along with current US reporting requirements.

1. CDC and Healthcare Infection Control Practices Advisory Committee (HICPAC) guidelines^{4,69}
2. American College of Surgeons and Surgical Infection Society SSI Guidelines⁷⁰
3. World Health Organization 2018⁷¹
4. National Institute for Health and Clinical Excellence (NICE)—United Kingdom 2008^{57,58}

5. SHEA Expert Guidance: Infection Prevention in the Operating Room Anesthesia Work Area⁷²
6. American Society of Health-System Pharmacists (ASHP) Clinical Practice Guideline for Antimicrobial Prophylaxis in Surgery 2013⁷³
7. Institute for Healthcare Improvement (IHI)⁷⁴
 - a. The IHI created a nationwide quality improvement project to improve outcomes in hospitalized patients,^{75,76} including 6 preventive measures for SSI that are also included in the 100,000 and 5 Million Lives Campaigns.^{75,76}
8. Federal requirements
 - a. Centers for Medicare & Medicaid Services (CMS)
 - i. In accordance with the Deficit Reduction Act of 2005, US hospitals that are paid by Medicare under the acute-care inpatient prospective payment system receive their full Medicare Annual Payment Update only if they submit required quality measure information to CMS.
 - ii. In addition, US acute-care hospitals submit data to the NHSN for complex SSIs following colon surgery and abdominal hysterectomy. These data are publicly reported on the CMS Hospital Care Compare website^{77,78} and are used to determine pay-for-performance in both the Hospital-Acquired Condition Reduction Program⁷⁹ and the Hospital-Value Based Purchasing Program.⁸⁰
 - iii. Accrediting organizations with deeming authority granted by the CMS, such as The Joint Commission and Det Norske Veritas Healthcare (DNV), verify that CMS requirements are met as part of the accreditation process.
- c. Ensure that education and feedback regarding SSI rates and specific measures that can be used to prevent infection filter down to all frontline multidisciplinary HCPs providing care in the perioperative⁸⁴ and postoperative settings.⁸⁵
3. Education of patients and families. Provide education for patients and patients' families to reduce risk associated with intrinsic patient-related SSI risk factors.^{86,87}
4. Computer-assisted decision support and automated reminders
 - a. Several institutions have successfully employed computer-assisted decision support methodology to improve the rate of appropriate administration of antimicrobial prophylaxis (including re-dosing during prolonged cases).⁸⁸⁻⁹¹
 - b. Computer-assisted decision support can be time-consuming to implement,⁷² and institutions must appropriately validate computer-assisted decision support systems after implementation to ensure that they are functioning appropriately.⁹²
5. Utilization of automated data
 - a. Install information technology infrastructure to facilitate data transfer, receipt, and organization to aid with tracking of process and outcome measures.
 - b. Consider use of data mining software to identify potential SSIs which can then be further evaluated.
 - c. Consider leveraging existing electronic health record capabilities to provide process measure information that informs improvement approaches.

Infrastructure requirements

Facilities performing surgery should have the following elements in place:

1. Trained infection prevention personnel
 - a. Infection preventionists (1) must be specifically trained in methods of SSI surveillance, (2) must have knowledge of and the ability to prospectively apply the CDC/NHSN definitions for SSIs, (3) must possess basic computer and mathematical skills, and (4) must be adept at providing feedback and education to healthcare personnel (HCP) when appropriate.^{4,81}
 - b. Having an increased number of infection preventionists, certified infection preventionists, and a hospital epidemiologist are associated with lower rates of SSI. A specific threshold for staffing has not been defined.⁸²
2. Education for HCP
 - a. A surgeon leader or champion can be a critical partner in changing culture and improving adherence to prevention practices.
 - b. Regularly provide education to surgeons and perioperative personnel through continuing education activities directed at minimizing perioperative SSI risk through implementation of recommended process measures.
 - i. Combine several educational components into concise, efficient, and effective recommendations that are easily understood and remembered.⁸³
 - ii. Provide education regarding the outcomes associated with SSI, risks for SSI, and methods to reduce risk to all surgeons, anesthesiologists, and perioperative personnel.

Section 4: Recommended strategies to prevent SSI

Recommendations are categorized as either (1) essential practices that should be adopted by all acute-care hospitals or (2) additional approaches that can be considered when hospitals have successfully implemented essential practices and seek to further improve outcomes in specific locations and/or patient populations. Essential practices include recommendations in which the potential to affect HAI risk clearly outweighs the potential for undesirable effects. Additional approaches include recommendations in which the intervention is likely to reduce HAI risk but there is concern about the risks for undesirable outcomes, recommendations for which the quality of evidence is low, or recommendations where the evidence supports the effect of the intervention in select settings (e.g., during outbreaks) or for select patient populations. Hospitals can prioritize their efforts by initially implementing infection prevention approaches listed as essential practices. If HAI surveillance or other risk assessments suggest that there are ongoing opportunities for improvement, hospitals should consider adopting some or all of the infection prevention approaches listed as additional approaches. These approaches can be implemented in specific locations or patient populations or can be implemented hospital-wide, depending on outcome data, risk assessment, and/or local requirements. Each infection prevention recommendation is given a quality of evidence grade (Table 2).

Essential practices for preventing SSI recommended for all acute-care hospitals

1. **Administer antimicrobial prophylaxis according to evidence-based standards and guidelines.**⁷⁵ (Quality of evidence: HIGH)
 - a. Begin administration within 1 hour prior to incision to maximize tissue concentration.^{73,93,94} Administering an antimicrobial agent <1 hour prior to incision is effective; some studies show superior efficacy for administration

between 0 and 30 minutes prior to incision compared with administration between 30 and 60 minutes prior to incision.^{95,96}

- i. Two hours are allowed for the administration of vancomycin and fluoroquinolones due to longer infusion times.
 - ii. For cesarean delivery, administer antimicrobial prophylaxis prior to skin incision rather than after cord clamping.⁹⁷
 - iii. In procedures using “bloodless” techniques, many experts believe that antimicrobial agents should be infused prior to tourniquet inflation, though data are lacking to inform this recommendation.⁹⁸
- b. Select appropriate antimicrobial agents based on the surgical procedure, the most common pathogens known to cause SSI for the specific procedure, and published recommendations.⁷³
- i. Although it is not recommended to routinely use vancomycin, this agent should be considered in patients who are known to be MRSA colonized (including those identified on preoperative screening), particularly if the surgery involves prosthetic material.
- c. Obtain a thorough allergy history. Self-reported β -lactam allergy has been linked to a higher risk of SSI due to use of alternative, non- β -lactam and often inferior antibiotics, and many patients with a self-reported β -lactam allergy can safely receive a β -lactam antibiotic as prophylaxis.^{99–101}
- d. Discontinue antimicrobial agents after incisional closure in the operating room.⁷³
- i. Although some guidelines suggest stopping the antimicrobial agents within 24 hours of surgery, there is no evidence that antimicrobial agents given after incisional closure contribute to reduced SSIs¹⁰² even when drains are inserted during the procedure.¹⁰³ In contrast, antibiotics given after closure contribute to increased antimicrobial resistance^{104,105} and increased risk of *Clostridioides difficile* infection¹⁰⁶ and acute kidney injury.¹⁰⁷
 - ii. In a single-center, retrospective, cohort study comparing joint arthroplasty, patients who received a single dose of antibiotic prophylaxis (no additional doses after skin closure) versus 24-hour antibiotic administration, there were no differences in the following outcomes between these 2 groups: prosthetic joint infection, superficial infection, 90-day reoperation, and 90-day complications.¹⁰⁸
- e. Adjust dosing based on patient weight,⁷³ according to the following examples:
- i. For cefazolin, use 30–40 mg/kg for pediatric patients, use 2 grams for patients weighing ≤ 120 kg, and 3 grams for patients weighing > 120 kg.^{109,110} Although data are conflicting regarding the role of 3 grams of cefazolin dosing in reducing SSI in obese patients, multiple studies have shown a benefit compared to 2-gram dosing in this patient population,^{110–112} with few adverse events from a single dose of 3 grams versus 2 grams of cefazolin. Although some hospitals use 1 gram for adult patients weighing ≤ 80 kg, there is no harm associated with giving a 2-gram dose.
 - ii. Dose vancomycin at 15 mg/kg.¹¹³
 - iii. Dose gentamicin at 5 mg/kg for adult patients and 2.5 mg/kg for pediatric patients. For morbidly obese

patients receiving gentamicin, use the ideal weight plus 40% of the excess weight for dose calculation.¹¹⁴

- f. Re-dose prophylactic antimicrobial agents for lengthy procedures and in cases with excessive blood loss during the procedure (ie, $> 1,500$ mL).⁷³ Re-dose prophylactic antimicrobial agents at intervals of 2 half-lives (measured from the time the preoperative dose was administered) in cases that exceed this period. For example, re-dose cefazolin after 4 hours in procedures > 4 hours long.⁷³
2. **Use a combination of parenteral and oral antimicrobial prophylaxis prior to elective colorectal surgery to reduce the risk of SSI.**^{115,116} (Quality of evidence: HIGH)
- a. A 2019 meta-analysis of 40 studies (28 randomized clinical trials [RCTs] and 12 observational studies) found that the combination of parenteral and oral antimicrobial prophylaxis and mechanical bowel preparation prior to elective colorectal surgery significantly reduces SSI, postoperative ileus, anastomotic leak, and 30-day mortality, without an increase in *C. difficile* infection.¹¹⁶ In 2021,¹¹⁷ the meta-analysis was updated to include the results from the MOBILE and ORALEV trials, which further demonstrated the decreases shown in 2019,^{119,120} along with data showing that oral antimicrobial prophylaxis alone without mechanical bowel preparation significantly reduces SSI, anastomotic leak, and 30-day mortality.^{121,122} We continue to recommend the combination of parenteral and oral antimicrobial prophylaxis and mechanical bowel preparation prior to elective colorectal surgery, unless there is a contraindication to mechanical bowel preparation, in which case, only parenteral and oral antimicrobial prophylaxis should be administered.
 - b. Use of combination parenteral and oral antimicrobial agents to reduce the risk of SSI should be considered in any surgical procedure where entry into the colon is possible or likely, as in gynecologic oncology surgery.
 - c. Mechanical bowel preparation without use of oral antimicrobial agents does not decrease the risk of SSI.¹¹⁵ A recent prospective randomized multicenter trial confirmed earlier meta-analysis findings, with significantly higher SSI and anastomotic leakage in patients who received mechanical bowel preparation without oral antimicrobial agents.¹²²
3. **Decolonize surgical patients with an antistaphylococcal agent in the preoperative setting for orthopedic and cardiothoracic procedures.** (Quality of evidence: HIGH). **Decolonize surgical patients for other procedures at high risk of staphylococcal SSI, such as those involving prosthetic material.** (Quality of evidence: LOW)
- a. Decolonization refers to the practice of treating patients with an antimicrobial and/or antiseptic agent to suppress *S. aureus* colonization inclusive of both methicillin-susceptible *S. aureus* (MSSA) and methicillin-resistant *S. aureus* (MRSA).
 - i. Published data are most supportive of using intranasal mupirocin and chlorhexidine bathing. There are some preliminary data on intranasal povidone-iodine administered immediately before surgery. This approach may have practical advantages, but more data are needed.¹²⁴ Fewer data exist for other alternative strategies such as intranasal alcohol-based antiseptics and phototherapy.
 - ii. The strongest data recommend up to 5 days of intranasal mupirocin (twice daily) and bathing with chlorhexidine gluconate (CHG) (daily).

- b. A meta-analysis of 17 studies of patients undergoing cardiac or orthopedic procedures concluded that decolonization strategies prevent *S. aureus* SSIs.¹²⁵
- c. Some trials demonstrated that preoperative screening for *S. aureus*, combined with intranasal mupirocin and CHG bathing, was effective in reducing SSI.
- i. For example, a randomized, double-blind, placebo-controlled, multicenter trial showed that rapid identification of *S. aureus* nasal carriers, followed by decolonization with intranasal mupirocin and CHG bathing was associated with a >2-fold reduction in the risk for post-operative infection due to *S. aureus* and an almost five-fold reduction in incidence of deep-incisional SSI due to *S. aureus*.¹²⁶ Patients undergoing clean procedures (eg, cardiothoracic, orthopedic, vascular) who were randomized to decolonization also had reduced 1-year mortality compared with those patients who were randomized to the placebo.¹²⁷
 - ii. A 20-hospital, nonrandomized, quasi-experimental study of patients undergoing cardiac surgery or total joint arthroplasty found a significant decrease in deep-incisional or organ-space *S. aureus* SSI after implementing a bundle of interventions, including *S. aureus* nasal screening, decolonization of nasal carriers with mupirocin, CHG bathing for all patients, and perioperative antibiotic prophylaxis adjustment based on MRSA carriage status.¹²⁸
 - iii. Notably, universal decolonization for targeted procedures is likely more cost effective than screen-and-treat strategies.^{129,130} Universal decolonization may also be easier to implement.
 - iv. Some hospitals continue to use screen-and-treat strategies because the results from screening for MRSA colonization can guide antibiotic prophylaxis.
- d. In contrast, other trials that assessed a wide range of surgical specialties did not observe a protective effect against SSIs.
- i. A prospective, interventional, cohort study with cross-over design involving 21,000 patients concluded that universal, rapid screening for MRSA at admission combined with decolonization of carriers did not reduce the SSI rate due to MRSA.¹³¹ This study included 8 surgical specialties: abdominal surgery, orthopedics, urology, neurosurgery, cardiovascular surgery, thoracic surgery, plastic surgery, and solid-organ transplantation. Similarly, a prospective interventional cohort study of 10 hospitals did not find a decrease in MRSA clinical cultures when MRSA screening and decolonization were performed among 9 surgical specialties. However, when the analysis was limited to patients undergoing clean surgery, MRSA screening and decolonization was significantly associated with reductions in MRSA SSI rates.^{132,133} Clean surgery included cardiothoracic, neuro, orthopedic, plastic, and vascular surgery.
 - ii. A double-blinded, randomized-controlled trial involving >4,000 patients undergoing general, gynecologic, neurologic, or cardiothoracic surgery showed that universal intranasal mupirocin application, when not combined with CHG bathing, did not significantly reduce the *S. aureus* SSI rate.¹³⁴ In a secondary analysis of this data, the use of intranasal mupirocin was associated with an overall decreased rate of nosocomial *S. aureus* infections among the *S. aureus* carriers.
- e. A Cochrane review concluded that mupirocin decolonization of the nares alone may be effective, particularly in certain groups, including patients undergoing orthopedic and cardiothoracic procedures.¹³⁵ However, routine preoperative decolonization with mupirocin without screening may lead to mupirocin resistance.¹³⁶
- f. Routine decolonization with antiseptic agents such as intranasal povidone-iodine without screening can be performed because povidone-iodine resistance has not been observed.
- i. One single-center RCT comparing intranasal povidone-iodine with mupirocin in total joint arthroplasty and spinal surgery patients found that povidone-iodine and mupirocin were similarly effective.¹³⁷ In that RCT, topical CHG wipes in combination with povidone-iodine was given within 2 hours of surgery versus with mupirocin during the 5 days before surgery.¹³⁷ There was no significant difference between deep SSI rates when comparing those who received povidone-iodine with those who received mupirocin.
 - ii. Two quasi-experimental, single-center studies of intranasal povidone-iodine decolonization reported a significant reduction in SSIs when compared with standard care among preintervention groups. One study paired intranasal povidone-iodine decolonization with CHG wipes and oral povidone-iodine rinse for elective orthopedic surgery¹³⁸; the other study paired it with CHG wipes or baths and povidone-iodine skin antiseptics for urgent lower extremity repairs of fractures that required hardware.¹³⁹
- g. Data are mixed on at-home preoperative bathing with CHG-containing products alone for patients not known to be colonized with *Staphylococcus aureus*.
- i. Preoperative bathing with agents such as CHG has been shown to reduce bacterial colonization of the skin.^{140,141} Several studies have examined the utility of preoperative showers, but none has definitively proven that they decrease SSI risk. A Cochrane review evaluated the evidence for preoperative bathing or showering with antiseptics for SSI prevention.¹⁴² Six RCTs evaluating 4% CHG use were included in the analysis, with no clear evidence of benefit noted. Several of these studies had methodologic limitations and were conducted several years ago. Thus, the role of preoperative bathing in SSI prevention remains uncertain.
 - ii. To achieve the maximum antiseptic effect of CHG, adequate levels of CHG must be achieved and maintained on the skin. Typically, adequate levels are achieved by allowing CHG to dry completely. Additional strategies for preoperative bathing with CHG, such as preimpregnated cloths, have shown promise,¹⁴³⁻¹⁴⁵ but data are currently insufficient to support this approach.
4. **Use antiseptic-containing preoperative vaginal preparation agents for patients undergoing cesarean delivery or hysterectomy.** (Quality of evidence: MODERATE)
- a. Use of povidone-iodine or CHG-based vaginal preparation agents immediately before cesarean delivery reduces endometritis by 59%, with possibly even greater benefit among women in labor.¹⁴⁶ Products should be chosen and used in accordance with manufacturer's instructions for use.

- b. Vaginal preparation with antiseptic solution is also recommended for elective hysterectomy.¹⁴⁷
5. **Do not remove hair at the operative site unless the presence of hair will interfere with the surgical procedure.**^{4,119} (Quality of evidence: MODERATE)
- a. If hair removal is necessary in elective procedures, remove hair outside the operating room using clippers or a depilatory agent.
- b. Razors may be acceptable for hair removal in a subset of procedures (eg, procedures involving male genitalia). One small, single-center, RCT demonstrated that clipping hair on the scrotum can cause more skin trauma than razors; clipping hair did not decrease the rate of SSI.¹⁴⁸
6. **Use alcohol-containing preoperative skin preparatory agents in combination with an antiseptic.** (Quality of evidence: HIGH)
- a. Alcohol is highly bactericidal and effective for preoperative skin antiseptics, but it does not have persistent activity when used alone. Rapid, persistent, and cumulative antiseptics can be achieved by combining alcohol with CHG or an iodophor.¹⁴⁹ Alcohol is contraindicated for certain procedures due to fire risk, including procedures in which the preparatory agent may pool or not dry (eg, involving hair). Alcohol may also be contraindicated for procedures involving mucosa, cornea, or ear.
- b. The most effective antiseptic to combine with alcohol remains unclear; however, data from recent trials favor the use of CHG–alcohol over povidone-iodine–alcohol.
- i. A Cochrane review of 13 studies, published in 2015, was inconclusive regarding the best strategy for preoperative skin antiseptics.¹⁵⁰ Only 1 of these studies compared 0.5% CHG–alcohol to povidone-iodine–alcohol.
- ii. Four RCTs (3 single center and 1 multicenter) have compared CHG–alcohol to povidone-iodine–alcohol.
- a) Tuuli *et al*¹⁵¹ conducted a single-center RCT of 1,147 women undergoing cesarean delivery. Women randomized to receive CHG–alcohol had a 45% reduction in SSI compared to women randomized to receive povidone-iodine–alcohol (relative risk, 0.55; 95% confidence interval, 0.34–0.90; $P = .02$).
- b) Ritter *et al*¹⁵² conducted a single-center RCT of 279 patients undergoing lower-limb procedures. Patients randomized to receive povidone-iodine–alcohol had a 3.5-fold higher rate of wound healing complications, including SSI, compared with patients randomized to receive CHG–alcohol.
- c) Broach *et al*¹⁵³ conducted a single-center, noninferiority RCT of 802 patients undergoing elective, clean-contaminated colorectal procedures. The SSI rate was higher among patients randomized to receive povidone-iodine–alcohol (18.7% vs 15.9%), which failed to meet criterion for noninferiority compared to CHG–alcohol.
- d) Charehbili *et al*¹⁵⁴ conducted a multicenter, cluster-randomized trial with crossover among 3,665 patients undergoing breast, vascular, colorectal, gallbladder, or orthopedic procedures. No difference in SSI rates was observed between the 2 groups, but some concerns were raised about the methods, including cluster sample size, number of clusters, and how the treatment period was analyzed.¹⁵⁵
- iii. CHG–alcohol is the antiseptic of choice for patients with *S. aureus* colonization.¹²⁸
- iv. In the absence of alcohol, CHG may have advantages over povidone-iodine, including longer residual activity and activity in the presence of blood or serum.^{156,157}
- v. Antiseptics are not interchangeable. Follow manufacturer's instructions to ensure correct application. Topical CHG preparations may be contraindicated for use in mouth, eyes and ears, patients with skin disease involving more than the superficial layers of skin, and procedures involving the meninges. Use of topical CHG preparations for preterm infants is controversial due to concerns for skin toxicity, absorption, and resultant toxicity including neurotoxicity.¹⁵⁸ However, apart from these specific contraindications, topical CHG for skin antiseptics and SSI prevention has been shown to be safe.^{158–162}
7. **For procedures not requiring hypothermia, maintain normothermia (temperature >35.5°C) during the perioperative period.** (Quality of evidence: HIGH)
- a. Even mild hypothermia can increase SSI rates. Hypothermia may directly impair neutrophil function or impair it indirectly by triggering subcutaneous vasoconstriction and subsequent tissue hypoxia. Hypothermia may increase blood loss, leading to wound hematomas or the need for transfusion—both of which can increase SSI rates.¹⁶³
- b. RCTs have shown the benefits of both preoperative and intraoperative warming in reducing SSI rates and intraoperative blood loss.^{164–166}
- c. Preoperative normothermia may be most beneficial¹⁶⁷; patients who received 30 minutes of preoperative warming had lower intraoperative hypothermia rates.¹⁶⁸ One study used 2 hours of preoperative warming, but a meta-analysis suggested that 30 minutes should be sufficient.
- d. Patients who are hypothermic at the end of surgery may remain hypothermic for up to 5 hours. Although there is not a standardized duration of postoperative warming, one study used 2 hours of postoperative warming and showed reduced rates of SSI.
8. **Use impervious plastic wound protectors for gastrointestinal and biliary tract surgery.** (Quality of evidence: HIGH)
- a. A wound protector, a plastic sheath that lines a wound, facilitates retraction of an incision during surgery without the need for additional mechanical retractors.
- b. A recent meta-analysis of 14 randomized clinical trials in 2,689 patients reported that the use of a plastic wound protector was associated with a 30% decrease in risk of SSI.¹⁶⁹
- i. There was a significant trend toward greater protective effect using a dual ring protector as compared to a single ring protector: 29% decrease in risk of SSI for dual ring and 16% decrease in risk of SSI for single ring.¹⁶⁹
- ii. Another prospective randomized study of dual ring protectors in pancreatectomy showed a reduction in SSI rate from 44% to 21% ($P = .011$) with the use of a dual ring protector.¹⁷⁰
9. **Perform intraoperative antiseptic wound lavage.**¹⁷¹ (Quality of evidence: MODERATE)
- a. Wound lavage is a common practice, although the solution and volume used for lavage differs among surgeons.

- b. Evidence does not support saline lavage (nonantiseptic lavage) to reduce SSIs.^{171,172}
- c. Several systematic reviews and meta-analyses support the use of prophylactic intraoperative wound irrigation with sterile dilute povidone-iodine lavage to decrease the risk of SSIs. One systematic review and meta-analysis published in 2017 evaluated 21 RCTs and concluded that lavage with sterile dilute povidone-iodine decreased the risk of SSI compared to nonantiseptic lavage (odds ratio [OR], 0.31; 95% confidence interval [CI], 0.13–0.73).^{102,173} This study reported no benefit from antibiotic irrigation and discouraged this practice.
- d. A systematic review and network meta-analysis published in 2021 reported that relative to saline lavage, both antibiotic irrigation (OR, 0.439; 95% CI, 0.282–0.667) and sterile dilute povidone-iodine (OR, 0.573; 95% CI, 0.321–0.953) decreased the risk of SSI. A third systematic review and meta-analysis published in 2015 reported a similar benefit of antibiotic irrigation and sterile dilute povidone-iodine in the subgroup analysis focused on colorectal surgery.^{174,175} Data were mixed in a different meta-analysis published in 2019,¹⁷⁶ potentially due to whether the antibiotic lavage (typically a β -lactam or aminoglycoside agent) was used in clean–clean-contaminated or contaminated–dirty wounds.
- e. We recommend the use of dilute povidone-iodine lavage over saline lavage, making sure that sterility is maintained during preparation and administration to enhance patient safety. We recommend studying antibiotic irrigation versus dilute povidone-iodine irrigation in an RCT focused on intra-abdominal surgery that is contaminated–dirty.
- f. Given the dearth of povidone-iodine solutions formally labeled “sterile,” we advise surgeons to educate themselves as to their options and to carefully weigh the risks and benefits of using povidone-iodine solutions available at their facility.
- g. Bacitracin is contraindicated. The FDA withdrew injectable bacitracin from the market because safety concerns outweighed the benefits. This was based on case reports of intraoperative anaphylactic shock associated with bacitracin irrigation.¹⁷⁷
- h. Other agents worth additional study include polyhexanide and rifampicin in certain patient populations.^{178,179}
- 10. Control blood-glucose level during the immediate postoperative period for all patients.**⁹⁴ (Quality of evidence: HIGH)
- a. Monitor and maintain postoperative blood-glucose level regardless of diabetes status.
- b. Maintain postoperative blood-glucose level between 110 and 150 mg/dL. Increased glucose levels during the operational procedure are associated with higher levels in the postoperative setting.¹⁸⁰ Studies on postoperative blood glucose have focused on monitoring through postoperative day 1–2; however, heterogeneity between studies makes it impossible to recommend a definitive window for postoperative blood-glucose control other than 24–48 hours.^{94,180–185}
- c. The ideal method for maintaining target postoperative blood-glucose level remains unknown. Generally, continuous insulin-infusion protocols lead to better control than subcutaneous insulin (sliding scale) strategies.¹⁸⁶ Continuous insulin infusion commonly requires intensive monitoring; thus, its use in the ambulatory surgery is often not feasible.
- d. Intensive postoperative blood-glucose control (targeting levels <110 mg/dL) has not consistently shown reduced risk of SSI. Although some studies have demonstrated decreased SSI rates,¹⁸⁷ others have demonstrated higher rates of hypoglycemia and adverse outcomes including stroke and death.¹⁸⁸
- 11. Use a checklist and/or bundle to ensure compliance with best practices to improve surgical patient safety.** (Quality of evidence: HIGH)
- a. The World Health Organization (WHO) checklist is a 19-item surgical safety checklist to improve adherence with best practices.¹⁸⁹
- i. A multicenter, quasi-experimental study conducted across 8 countries demonstrated that use of the WHO checklist led to lower surgical complication rates, including SSI and death.¹⁹⁰
- ii. These findings have been confirmed in subsequent single- and multicenter quasi-experimental studies.^{191,192}
- b. Overall, the use of bundles can reduce SSI, but the exact elements needed in a bundle are unknown.¹⁹³ This issue is important because some elements have considerable cost and logistical implications, so it is important to understand the impact of individual elements outside a bundle.¹⁹³
- 12. Perform surveillance for SSI.** (Quality of evidence: MODERATE)
- a. Identify high-risk, high-volume operative procedures to be targeted for SSI surveillance based on a risk assessment of patient populations, operative procedures performed, and available SSI surveillance data. Some surveillance is also mandated by federal and state regulations.
- b. Identify, collect, store, and analyze data needed for the surveillance program.⁴
- i. Develop a database for storing, managing, and accessing data collected on SSIs.
- ii. Implement a system for collecting data needed to identify and report SSIs. This is discussed in Section 2. Consider collecting data on patient comorbidities (including American Society of Anesthesiology [ASA] score and specific risk factors such as body mass index and diabetes), surgical factors (including wound class, operative duration), process measures (including completion of essential practices discussed in this section), and specifics of SSI (including depth, infecting organism, and antimicrobial susceptibilities).
- iii. Develop a system for routine review and interpretation of SSI rates and/or SIRs to detect significant increases or outbreaks and to identify areas where additional resources might be needed to improve SSI rates.^{34,194} If increased rates are identified, determine the number of infections that were potentially preventable.¹⁹⁵
- c. Convene key national agencies, organizations, and societies to evaluate. Where possible, align definitions and reporting requirements.
- 13. Increase the efficiency of surveillance by utilizing automated data.** (Quality of evidence: MODERATE)
- a. Implement a method to electronically transmit data to infection prevention and control personnel needed to determine denominator data and calculate SSI rates for various procedures. This might include procedure data, process measure data, readmission and rehospitalization data, postoperative antimicrobial data, microbiology data, and diagnosis and procedure codes.^{54,196–199}

14. **Provide ongoing SSI rate feedback to surgical and perioperative personnel and leadership.** (Quality of evidence: MODERATE)
 - a. Routinely audit and provide confidential feedback on SSI rates or SIRs and adherence to process measures to individual surgeons, the surgical division and/or department chiefs, and hospital leadership.^{4,200}
 - i. Provide risk-adjusted SSI SIRs for each type of procedure under surveillance and reported to the NHSN. For procedures not reported to the NHSN, there may be alternative data to review through surveillance programs such as National Surgical Quality Improvement Program (NSQIP).²⁰¹
 - ii. Anonymously benchmark procedure-specific, risk-adjusted SSI SIRs among peer surgeons.
15. **Measure and provide feedback to HCP regarding rates of compliance with process measures.**⁹⁴ (Quality of evidence: LOW)
 - a. Routinely provide feedback to surgical staff, perioperative personnel, and leadership regarding compliance with targeted process measures.¹⁹⁵
16. **Educate surgeons and perioperative personnel about SSI prevention measures.** (Quality of evidence: LOW)
 - a. Include risk factors, outcomes associated with SSI, local epidemiology (eg, SSI rates by procedure, rate of methicillin-resistant *Staphylococcus aureus* [MRSA] infection in a facility), and essential prevention measures.
17. **Educate patients and their families about SSI prevention as appropriate.** (Quality of evidence: LOW)
 - a. Provide instructions and information to patients prior to surgery describing strategies for reducing SSI risk. Specifically provide preprinted materials to patients.²⁰²
 - b. Examples of printed materials for patients are available from the following web pages:
 - i. JAMA patient page: Wound Infections⁸⁷
 - ii. Surgical Care Improvement Project Tips for Safer Surgery²⁰³
 - iii. CDC Frequently Asked Questions About Surgical-Site Infections²⁰⁴
 - iv. SHEA Infection Prevention Handout for Patients and Visitors²⁰⁵
18. **Implement policies and practices to reduce the risk of SSI for patients that align with applicable evidence-based standards, rules and regulations, and medical device manufacturer instructions for use.**^{4,94} (Quality of evidence: MODERATE)
 - a. Implement policies and practices to reduce modifiable risk factors (Table 1), including the following:
 - i. Optimally disinfect the hands of the surgical team members.
 - ii. Adhere to hand hygiene practices, including nonsurgeon members of the operating team.²⁰⁶
 - iii. Reduce unnecessary traffic in operating rooms.^{207,208}
 - iv. Avoid use of nonsterile water sources in the operating room.^{209,210}
 - v. Properly care for and maintain the operating rooms, including appropriate air handling, pressure relative to hallway, temperature, humidity, and optimal cleaning and disinfection of equipment and the environment.⁴
 - vi. Maintain asepsis from the start of preparation of surgical instruments on the sterile field through wound closure and dressing.
 - vii. Establish a robust infection control risk assessment program focused on mitigating risk during construction projects.
 - viii. Proactively address potential risks from supply-chain shortages and communicate to frontline teams.
 - ix. Discuss any staffing shortages and potential impact on outcomes as they relate to compliance with SSI prevention measures.
19. **Observe and review operating-room personnel and the environment of care in the operating room and in central sterile reprocessing.** (Quality of evidence: LOW)
 - a. Perform direct observation audits of operating-room personnel to assess operating-room processes and practices to identify infection control lapses, including but not limited to adherence to process measures (antimicrobial prophylaxis choice, timing and duration protocols, hair removal, etc), surgical hand antisepsis, patient skin preparation, operative technique, surgical attire (wearing and/or laundering outside the operating room), and level of operating-room traffic.²¹¹⁻²¹⁵ Perform remediation when breaches of standards are identified.
 - i. Operating-room personnel should include surgeons, surgical technologists, anesthesiologists, circulating nurses, residents, medical students, trainees, and device manufacturer representatives.²¹¹
 - b. Perform direct observation audits of environmental cleaning practices in the operating room, instrument reprocessing (sterilization) area, and storage facilities.
 - i. Review instrument reprocessing and flash sterilization or immediate-use steam sterilization (IUSS) logs.
 - ii. Review maintenance records for operating room heating, ventilation, and air conditioning (HVAC) system including, results of temperature, relative humidity, and positive air pressure maintenance testing in the operating rooms(s).
 - c. Provide feedback and review infection control measures with operating-room and environmental personnel.

Additional approaches for preventing SSI

These additional approaches can be considered when hospitals have successfully implemented essential practices and seek to further improve outcomes in specific locations and/or patient populations.

1. **Perform an SSI risk assessment.** (Quality of Evidence: LOW)
 - a. Convene a multidisciplinary team (eg, surgical leadership, hospital administration, quality management services, and infection control) to identify gaps, improve performance, measure compliance, assess impacts of interventions, and provide feedback.²¹⁶
2. **Consider use of negative-pressure dressings in patients who may benefit.** (Quality of Evidence: MODERATE)
 - a. Negative-pressure dressings placed over closed incisions are thought to work by reducing fluid accumulation in the wound. Recent systematic reviews have demonstrated a significant reduction in SSI with their use.²¹⁷⁻²¹⁹
 - b. These dressings have been particularly noted to reduce SSIs in patients who have undergone abdominal surgery^{220,221} and joint arthroplasty,^{222,223} although not all studies have

- shown benefit²²⁴ and some indicate benefit only in a subset of procedures such as revision arthroplasty.²²²
- c. Guidance is lacking regarding which patients most benefit from the use of negative-pressure dressings, with some evidence that the benefit increases with age and body mass index.²²⁵
 - d. Negative-pressure dressings seem most successful at reducing superficial SSIs,²²⁶ but some risk of blistering has been observed.²²² These blisters could lead to breaks in the skin that might increase risk of infection.
 - e. It is important to assess the ability of the patient to manage a negative-pressure dressing, particularly if used in the ambulatory setting.
 - f. Cost-effectiveness studies of negative-pressure dressings are needed.
3. **Observe and review practices in the preoperative clinic, postanesthesia care unit, surgical intensive care unit, and/or surgical ward.** (Quality of evidence: MODERATE)
 - a. Perform direct observation audits of hand-hygiene practices among all HCP with direct patient contact.²¹³
 - b. Evaluate wound care practices.²²⁷
 - c. Perform direct observation audits of environmental cleaning practices.
 - d. Provide feedback and review infection control measures with HCP in these perioperative care settings.
 4. **Use antiseptic-impregnated sutures as a strategy to prevent SSI.** (Quality of evidence: MODERATE)
 - a. Human volunteer studies involving foreign bodies have demonstrated that the presence of surgical sutures decreases the inoculum required to cause an SSI from 10^6 to 10^2 organisms.²²⁸
 - b. Some trials have shown that surgical wound closure with triclosan-coated polyglactin 910 antimicrobial sutures may decrease the risk of SSI compared to standard sutures.^{229,230} For example, an RCT of 410 colorectal surgeries concluded that the rate of SSI decreased >50% among patients who received antimicrobial sutures (9.3% in control group vs 4.3 among cases; $P = .05$).²³¹
 - c. In contrast, a systematic review and meta-analysis evaluated 7 RCTs and concluded that neither SSI rates (OR, 0.77; 95% CI, 0.4–1.51; $P = .45$) nor wound dehiscence rates (OR, 1.07; 95% CI, 0.21–5.43; $P = .93$) were statistically different compared to controls.²³² In addition, a small study raised concern about higher wound dehiscence rates associated with using these antimicrobial sutures.²³³
 - d. The impact of routinely using antiseptic-impregnated sutures on the development of antiseptic resistance remains unknown.
- material. Vancomycin can also be used in the setting of a proven outbreak of SSIs due to MRSA.²³⁵
- i. Suspected high rates of MRSA SSI should not be used as justification for vancomycin use. In a cohort study of 79,092 surgical procedures, the primary reason for vancomycin perioperative prophylaxis was the perception of high facility rates of MRSA or high-risk procedure for MRSA. Patients who received vancomycin prophylaxis because of the perceived high facility risk of MRSA had no increase in prevalence of MRSA colonization compared with the general surgical population. The incidence of SSIs was the same regardless of vancomycin prophylaxis, but the incidence of acute kidney injury (AKI) was significantly higher among patients who received vancomycin.²³⁶
 - ii. In a retrospective cohort study of 79,058 surgical procedures, vancomycin perioperative prophylaxis was independently associated with significantly increased risk of AKI.¹⁰⁷
 - iii. Two meta-analyses of studies comparing glycopeptides to β -lactam antimicrobial prophylaxis concluded that there was no difference in rates of SSI between the 2 antimicrobial prophylaxis regimens.^{125,237}
- b. Vancomycin does not have activity against gram-negative pathogens and appears to have less activity against MSSA than β -lactam agents. The addition of vancomycin to standard antimicrobial prophylaxis has been done in specific circumstances, but the benefits should be weighed against the risks.^{73,237–239}
 - i. Among cardiac surgery patients, receipt of vancomycin in combination with a β -lactam for perioperative prophylaxis was associated with increased AKI compared with either antibiotic alone.^{107,240}
 - ii. In a cohort study of 70,101 surgical cases, vancomycin plus β -lactam combination prophylaxis was associated with a greater risk of AKI compared with vancomycin alone.²⁴¹ In that study, vancomycin plus a β -lactam reduced the incidence of SSIs following cardiothoracic procedures compared with either antibiotic alone. However, this antimicrobial combination did not reduce SSIs for orthopedic, vascular, hysterectomy, or colorectal procedures.
2. **Do not routinely delay surgery to provide parenteral nutrition.** (Quality of evidence: HIGH)
 - a. Preoperative administration of total parenteral nutrition (TPN) has not been shown to reduce the risk of SSI in prospective RCTs and may increase the risk of SSI.^{242,243}
 - b. Individual trials comparing enteral and parenteral perioperative nutrition and comparing immunomodulating diets containing arginine and/or glutamine to standard control diets tend to have very small sample sizes and fail to show significant differences in SSI rates. In 2 recent meta-analyses, however, postoperative infectious complications were reduced in patients receiving enteral diets containing glutamine and/or arginine administered either before or after the surgical procedure.^{244,245}
 3. **Do not routinely use antiseptic drapes as a strategy to prevent SSI.** (Quality of evidence: HIGH)
 - a. An incise drape is an adhesive film that covers the surgical incision site to minimize bacterial wound contamination from endogenous flora. These drapes can be impregnated with antiseptic chemicals such as iodophors.

Approaches that should not be considered a routine part of SSI prevention

1. **Do not routinely use vancomycin for antimicrobial prophylaxis.**⁷³ (Quality of evidence: MODERATE)
 - a. Vancomycin should not routinely be used for antimicrobial prophylaxis, but it can be an appropriate agent for specific scenarios.^{128,234} Reserve vancomycin for specific clinical circumstances, as in patients who are known to be MRSA colonized (including those identified on preoperative screening), particularly if the surgery involves prosthetic

- i. A 2007 Cochrane review of 5 trials concluded, nonantiseptic incise drapes were associated with a higher risk of SSIs compared to no incise drapes (RR, 1.23; 95% CI, 1.02–1.48)²⁴⁶ although this association may have been heavily weighted by one specific study.²⁴⁷
- ii. Two trials (abdominal and cardiac surgical patients) compared iodophor-impregnated drapes to no drapes.^{247,248} Although wound contamination was decreased in one trial,²⁴⁷ neither trial demonstrated that iodophor-impregnated drapes decreased the rate of SSI.
- iii. A nonrandomized retrospective study similarly concluded that impregnated drapes do not prevent SSI after hernia repair.²⁴⁹

Unresolved issues

1. Optimize tissue oxygenation at the incision site.

- a. In a meta-analysis of 5 studies, perioperative supplemental oxygen administration led to a relative SSI risk reduction of 25%. In contrast, a more recent meta-analysis of 15 studies was inconclusive.²⁵⁰ Additional studies published since the 2014 SHEA Compendium have similarly not shown a reduction in SSI in patients who received supplemental oxygen at a fraction of inspired oxygen (FiO₂) of 80%.^{251–253}
- b. Most trials compared 80% FiO₂ to 20%–35% FiO₂. The benefit of other oxygen concentrations remains unknown.
- c. The best available evidence for the use of supplemental oxygen is in patients undergoing high-risk surgery with general anesthesia using mechanical ventilation.^{254–256}
- d. Supplemental oxygen is most effective when combined with additional strategies to improve tissue oxygenation including maintenance of normothermia and appropriate volume replacement. Tissue oxygenation at the incision site depends on vasoconstriction, temperature, blood supply, and cardiac output.

2. Preoperative intranasal and pharyngeal CHG treatment for patients undergoing cardiothoracic procedures

- a. Although data from an RCT trial support the use of CHG nasal cream combined with 0.12% CHG mouthwash,²⁵⁷ CHG nasal cream is neither FDA approved nor commercially available in the United States.

3. Use of gentamicin-collagen sponges

- a. Gentamicin-collagen sponges have been evaluated as an intervention to decrease SSI among colorectal and cardiac surgical patients.
 - i. Colorectal surgical patients. Several single-center randomized trials demonstrated that gentamicin-collagen sponges decrease the risk of SSI following colorectal procedures.^{258–260} However, the rate of SSI was higher with the sponge in 2 recent, large, multicenter RCTs.^{261,262}
 - ii. Cardiothoracic surgical patients. Four RCTs have evaluated the use of gentamicin-collagen sponges in cardiothoracic surgery. Three of these trials demonstrated a decrease in SSIs and one demonstrated no difference.^{263–266} A recent meta-analysis combining these trials and 10 observational studies concluded that the risk of deep sternal wound infection was significantly lower in patients who received a gentamicin-collagen sponge than patients who did not (RR, 0.61; 95% CI, 0.39–0.98) despite significant heterogeneity among the trials.²⁶⁷

- b. Gentamicin-collagen sponges are not currently FDA approved for use in the United States.

4. Use of antimicrobial powder

- a. Multiple publications have examined the use of vancomycin powder in surgical incisions, especially for spinal and cranial procedures for which *S. aureus* is a primary pathogen.^{268,269} Although a few reviews report a lower rate of SSI in spinal surgery with the use of vancomycin powder,²⁷⁰ other references report a significant increase in the proportion of SSI with polymicrobial and gram-negative pathogens when they occur.^{271–273} In addition, a prospective randomized trial comparing the use of vancomycin powder in combination with intravenous vancomycin to the use of intravenous vancomycin alone found no benefit with the addition of vancomycin powder.²⁷⁴

5. Use of surgical attire

- a. Although there are longstanding traditions and opinions regarding surgical attire in the operating room, no strong evidence exists for many of them. It has not been demonstrated that surgical attire affects SSI rates.²⁷⁵ One approach to managing issues pertaining to surgical attire is to form a multidisciplinary body including infection control, surgery, nursing, and anesthesia to discuss and agree to some sensible, not overly aggressive or cumbersome attire standards, and to establish policies and procedures that are compliant with state and CMS requirements.²⁷⁵

Section 5: Performance measures

Internal reporting

These performance measures are intended to support internal hospital quality improvement efforts and do not necessarily address external reporting needs. The process and outcome measures suggested here are derived from published guidelines, other relevant literature, and the opinion of the authors. Report process and outcome measures to senior hospital leadership, nursing leadership, and clinicians who care for patients at risk for SSI (Table 4).

Process measures

EXAMPLE: Compliance with antimicrobial prophylaxis guidelines

1. Measure the percentage of procedures in which antimicrobial prophylaxis was provided appropriately. Appropriateness includes (1) correct antibiotic for specific surgery, (2) correct antibiotic dose, (3) administration start time within 1 hour of incision (2 hours allowed for vancomycin and fluoroquinolones), and (4) discontinuation of the agent after skin closure.
 - a. Numerator: Number of patients who appropriately received antimicrobial prophylaxis.
 - b. Denominator: Total number of selected operations performed.
 - c. Multiply by 100 so that measure is expressed as a percentage.

Outcome measures

EXAMPLE: Surgical site infection SIR

1. Use NHSN definitions and risk adjustment methods for measuring SSI incidence⁴³

Table 4. SSI Prevention Internal Reporting Process and Outcome Measures

Internal Reporting Process Measure Example: Compliance with Antimicrobial Prophylaxis Guidelines
Percentage of procedures in which antimicrobial prophylaxis was provided appropriately = (No. of patients who appropriately received antimicrobial prophylaxis/Total number of selected operations performed) ×100 1. Correct antibiotic for specific surgery 2. Correct antibiotic dose 3. Administrative start time within 1 hour of incision (2 hours allowed for vancomycin and fluroquinolones) 4. Discontinuation of agent after skin closure
Internal Reporting Outcome Measure Example: Surgical Site Infection Standardized Infection Ratio (SIR)
SIR = Ratio of observed number of SSIs (O)/Predicted number of SSIs (P) for a specific type of procedure ²⁷⁸

- a. SIR numerator: Number of surgical site infections following a specified type of procedure.
- b. SIR denominator: Total number of predicted SSIs following a specified type of procedure. The SIR denominator is calculated in NHSN using national baseline data and is risk adjusted for several facility, patient, and procedure-level factors.³⁴
- c. SIR is the ratio of the observed (O) number of SSIs that occurred compared to the predicted (P) number for a specific type of procedure: $SIR = O/P$.³⁴ Values that exceed 1.0 indicate that more SSIs occurred than expected. Importantly, SIR can only be calculated if the number of predicted HAIs is ≥ 1 . Thus, this approach may be more difficult for small surgical programs or if few procedures are performed for any 1 procedure type.²⁷⁶
- d. Risk adjustment using logistic regression and the SIR method generally provides better risk adjustment than the traditional NHSN risk index.^{281,285}

External reporting

There are many challenges in providing useful information to consumers and other working partners while preventing unintended consequences of public reporting of HAIs.^{283–285} Recommendations and requirements for public reporting of HAIs have been provided by HICPAC,^{286,287} the National Quality Forum,²⁸⁸ and the CMS²⁸⁹ (Table 5).

Outcome measures

1. External reporting measures now focus mostly on outcomes.
2. Since 2012, the CMS has imposed a reporting requirement for SSI data for inpatient abdominal hysterectomy and inpatient colon procedures.^{290,291}
3. Federal and state requirements
 - a. Federal requirements
 - i. CMS published a final rule in the *Federal Register* on August 18, 2011 that includes surgical site infection (SSI) reporting via the NHSN in the CMS Hospital Inpatient Quality Reporting (IQR) Program requirements for 2012.²⁸⁹ More specifically, the rule announced a reporting requirement for SSI data for inpatient abdominal hysterectomy and inpatient colon procedures.²⁹¹

Table 5. SSI Prevention External Reporting Outcome Measures

Federal requirements^a
1. Reported via CDC NHSN in the CMS Hospital Inpatient Quality Reporting program. ²⁸⁹ 2. Since 2012, SSI data reporting for inpatient abdominal hysterectomy and inpatient colon procedures has been required. ^{290,291} 3. Hospitals in states with a SSI reporting mandate must abide by their state's requirements, even if they are more extensive than federal requirements.
State requirements and collaboratives
1. In states with mandatory SSI reporting requirements, hospitals must collect and report the data required by the state. 2. Hospitals should check with the state or local health department for requirements.

Note. CDC, Centers for Disease Control and Prevention; NHSN, National Health Safety Network. CMS, Centers for Medicare & Medicaid Services; HICPAC, Healthcare Infection Control Practices Advisory Committee.

^aRecommendations and requirements for public reporting provided by HICPAC,^{286,287} the National Quality Forum,²⁸⁸ and the CMS.²⁸⁹

- ii. The requirements for SSI reporting to the NHSN for the hospital IQR program do not preempt or supersede state mandates for SSI reporting to NHSN (ie, hospitals in states with a SSI reporting mandate must abide by their state's requirements, even if they are more extensive than the requirements for this CMS program). NHSN users reporting SSI data to the system must adhere to the definitions and reporting requirements for SSIs as specified in the NHSN Patient Safety Component Protocol Manual.^{43,291}
- b. State requirements. Hospitals in states that have mandatory SSI reporting requirements must collect and report the data required by the state. For information on state requirements, check with your state or local health department.

External quality initiatives

Several external quality initiatives focused on SSI prevention are ongoing. The benefits from participation in these external quality initiatives are unknown but may include improvement in the culture of safety and patient outcomes, including decreased rates of SSI.²⁹²

Section 6: Implementation of SSI prevention strategies

SSI prevention science and education must be partnered with purposeful implementation of interventions to achieve desired outcomes. Beyond protocol development and educational efforts, this includes measurement of adherence to agreed-upon practices, understanding and addressing potential barriers to adherence, and frequent feedback to all partners.

Reliability is the frequency at which an intervention is completed when indicated. Implementation of any practice requires monitoring for reliability, commonly known as a process measure. In SSIs, process measurement is especially important to successful implementation due to the complexity of systems involved and of the outcome itself. Connecting a reduction or increase in SSI rates to utilization of a bundle is difficult without reliability measurement, and protocol adherence has been directly correlated to improved outcomes.²⁹³ Successful implementation efforts described in the literature have frequently failed to identify a single effective intervention, instead emphasizing the effect of process reliability.^{294–296}

Table 6. Fundamental Elements of Accountability and Engagement for SSI Prevention

Organizational Role	Responsibilities	Accountability
Senior management (executives, senior directors) (Note: regulatory requirement for US hospitals)	Ensure sufficient funds, expertise, and commitment to an infection prevention and control (IPC) program that effectively prevents healthcare-associated infections (HAIs) and the transmission of epidemiologically important pathogens.	Accountable for proper resource allocation and evaluation, including training, competency, and ancillary support (eg, data analysis).
Surgical services leadership (surgeon, anesthesia, perioperative nursing leaders)	Ensure all perioperative staff are aware of their roles and expectations as they relate to SSI prevention. Advocate for the support of senior leadership.	Direct evaluation of groups and practitioners, enforcing standards and correcting when necessary. Review of longitudinal outcome data and communication with all perioperative staff.
Surgical services staff (surgeons, anesthesiologists/CRNAs, perioperative nurses and technicians)	Ensure execution of prevention measures consistently for all procedures. Escalate questions and concerns to senior surgical leadership.	SSI prevention process measurement, individual reinforcement, support, and correction as indicated.
Pharmacists	Ensure proper medications for SSI prevention are available when needed. Promote evidence-based, cost-effective choice of antimicrobial prophylaxis.	Track utilization patterns and adverse drug events to ensure proper use of drugs for SSI prevention. Communicate changes and their rationale (eg, drug shortage, new evidence)
Infection preventionists	Ensure surveillance for SSI is thorough and aligns with national standards. Support prevention efforts as subject-matter experts, coaches, and observers of process and outcome. Educate staff and audit compliance on practical application ³⁶¹ of infection control related policies and processes	Validation of surveillance methodology with transparency to all partners. Assess SSI prevention system as a whole to identify gaps and opportunities.
Environmental services staff	Ensure correct processes for cleaning perioperative and related areas, and adequate number, training, and support of staff.	Track benchmarks and conduct process and performance reviews regularly.
Information services	Support SSI prevention efforts through data collection automation and analysis, leverage different platforms (electronic health record, billing databases) to ensure standard and consistent data streams.	Validate systems regularly and whenever updated, maintain flexibility for changes as needs evolve. Engage with other partners if changes are anticipated. Communicate changes to all partners.

High reliability can be achieved through different methods and conceptual frameworks. The following outline summarizes ways in which facilities have achieved reliability. Choice of a method for a given group depends on system context,^{297,298} local knowledge of improvement and implementation science, and resources available to support the effort.

1. Quality improvement tools

- a. Team projects. Implementation often occurs in the context of a team project, such as that used to teach and disseminate quality improvement methods. Utilizing a planned quality improvement project may be a good approach for initial implementation of an existing or novel bundled intervention.^{299–302} Because SSIs may present weeks to months after surgery and because new systems need time to adjust, SSI prevention implementation may take longer than the typical 90–120 days of a quality improvement project and may benefit from an iterative and adaptive approach over time.³⁰³
- b. Process mapping. Understanding the system involved may help in planning more effective interventions, particularly in resource-constrained settings.³⁰⁴
- c. Reliability measurement. Process reliability should be measured regularly. SSI prevention process measures like antibiotic choice or timing of administration of preoperative antibiotics may be measurable using existing data available in an electronic health record.³⁰⁵ Other behaviors, such as environmental cleaning practices, may require direct observation.³⁰⁶

- d. Feedback. Sharing results with working partners is an important way to change and solidify behavior. Increasing awareness among HCP throughout the surgical care continuum,^{31,307–310} including sharing outcome data with individual surgeons, has been effective in a variety of contexts.^{308,311}
 - e. Apparent cause analysis. Learning from failed processes or unwanted outcomes is a useful means to gain a shared mental model and advance efforts. Objective review of data helps avoid assigning blame to individuals and focusing on needed system improvements.
 - f. Surveillance and improvement networks. Networks of institutions within the US and internationally have arisen to collect data, learn collectively, and improve patient outcomes.^{312,313} Groups such as Solutions for Patient Safety,³¹⁴ the NSQIP,³¹⁵ and statewide collaboratives³¹⁶ have helped facilitate improvement through direct engagement or supplying data to drive interventions. Punitive approaches have been less effective at affecting improvement.²⁸³
- #### 2. Multidisciplinary approach (Table 6)
- a. Efforts to prevent SSIs should consider the large variety of touch points, risk factors, and partners needed to implement multiple effective strategies.^{31,295,296,317–319} Partners from all areas should be included in the prevention effort, such as preoperative clinic staff, perioperative staff, staff in sterile processing, postoperative staff, pharmacists, etc.
 - b. Frontline involvement. SSI prevention is not the sole responsibility of surgeons and involves mitigating risk inside and

outside operating rooms. Recruiting nonsurgeon groups, such as medical or nursing trainees or pharmacists³²⁰ to lead improvement efforts, has been shown to be effective.

- c. Education and reinforcement. Orienting patients, families, and care providers to the need to prevent SSI by implementing interventions pre-, intra-, and postoperatively is crucial. Emphasizing interventions that they can control has been effective at reducing SSIs.^{31,202,321–324} Education should be provided to patients and families in their primary languages.
3. Human factors engineering
 - a. Interventions that automate reminders (eg, alarms to prevent excessive door opening or electronic alerts to re-dose antibiotics)^{325,326} or processes themselves may be effective at preventing SSIs.^{325,327} Existing information systems, such as electronic health records, can be leveraged for this purpose as well as for standardizing evidence-based order sets.
 - b. Operating-room door openings are a surrogate marker for poor operating-room discipline.^{208,327,329} Agreeing on a limit for how many door openings during surgery are acceptable and staying below that limit have been associated with decreased incidence of SSIs.³²⁸ Communication between the surgeon and operating-room staff on the equipment needed prior to surgery can lead to fewer door openings.³²⁸ Operating-room personnel turnover during procedures has been associated with an increased risk of SSI, even after statistically adjusting for length of surgery.³³⁰ When possible, shift changes and breaks should wait until the procedure has ended.
 - c. Standardizing practices through the use of dedicated teams, checklists, and surgeon preference cards, and ensuring adequate staffing have all been effective strategies to implement interventions.^{31,208,331–333}
 - d. Interventions to prevent SSIs can be optimized by identifying the people (eg, preoperative nurse, operating room nurse, surgeon, patient, or family) needed to successfully implement the intervention and provide them with directed tools to support adherence with the intervention. The perspectives of each of these partners need to be considered to identify barriers and facilitators to intervention adherence.³³⁴
 4. Accountability
 - a. Accountability is an essential principle for preventing HAIs by ensuring evidence-based implementation strategies are used consistently, maximizing their effectiveness in preventing HAIs.
 - b. Engagement and commitment of executive and senior leadership are essential to setting goals, removing barriers, and justifying the effort to build and sustain improvements.^{319,335–337} Engaged local leaders (eg, a senior surgeon) also give the effort and expectations legitimacy.
 - c. Interventions, bundle components, and practices should be evidence-based as much as possible³³⁸ and should be deemed appropriate for the surgical population (eg, evidence from the adult population may not be appropriate to apply in a pediatric population).
 5. Safety culture and practices
 - a. SSI prevention efforts align well with, and may be contextualized within, patient and employee safety campaigns. However, culture change is a prolonged and ongoing process. SSI prevention should not be delayed until safety

culture is improved, but rather used as a concrete example of the benefits of safe behaviors.

Acknowledgments. The findings and conclusions in this report are those of the author and do not necessarily represent the official position of the Centers for Disease Control and Prevention (CDC).

Conflicts of interest. The following disclosures reflect what has been reported to SHEA. To provide thorough transparency, SHEA requires full disclosure of all relationships, regardless of relevancy to the topic. Such relationships as potential conflicts of interest are evaluated in a review process that includes assessment by the SHEA Conflict of Interest Committee and may include the Board of Trustees and Editor of *Infection Control and Hospital Epidemiology*. The assessment of disclosed relationships for possible conflicts of interest has been based on the relative weight of the financial relationship (i.e., monetary amount) and the relevance of the relationship (i.e., the degree to which an association might reasonably be interpreted by an independent observer as related to the topic or recommendation of consideration). D.J.A. is the owner of Infection Control Education for Major Sports, LLC, has grants from CDC and AHRQ and has received royalties for authorship on UpToDate. A.C.N. is the Chair DSMB, CAV-AVI Neonatal PK Study with Pfizer. All other authors report no conflicts of interest related to this article.

References

1. Anderson DJ, Podgorny K, Berrios-Torres SI, *et al.* Strategies to prevent surgical site infections in acute care hospitals: 2014 update. *Infect Control Hosp Epidemiol* 2014;35:605–627.
2. *The SHEA Handbook for SHEA-Sponsored Guidelines and Expert Guidance Documents*, 2021. Society for Healthcare Epidemiology of America website. <https://shea-online.org/wp-content/uploads/2022/02/2022-Handbook-Update-Approved-Posted.pdf>. Published August 2021. Accessed March 28, 2023.
3. National Health Safety Network. Current HAI Progress Report, 2021 Centers for Disease Control and Prevention website. <https://www.cdc.gov/hai/data/portal/progress-report.html>. Updated November 4, 2022. Accessed 2022.
4. Berrios-Torres SI, Umscheid CA, Bratzler D, *et al.* Centers for Disease Control and Prevention Guideline for prevention of surgical site infection, 2017. *JAMA Surg* 2017;152:784–791.
5. Baker AW, Dicks KV, Durkin MJ, *et al.* Epidemiology of surgical site infection in a community hospital network. *Infect Control Hosp Epidemiol* 2016;37:519–526.
6. Dencker EE, Bonde A, Troelsen A, Varadarajan KM, Sillesen M. Postoperative complications: an observational study of trends in the United States from 2012 to 2018. *BMC Surg* 2021;21:393.
7. Anderson DJ, Pyatt DG, Weber DJ, Rutala WA, North Carolina Department of Public Health HAIAG. Statewide costs of healthcare-associated infections: estimates for acute-care hospitals in North Carolina. *Am J Infect Control* 2013;41:764–768.
8. Gantz O, Zagadailov P, Merchant AM. The cost of surgical site infections after colorectal surgery in the United States from 2001 to 2012: a longitudinal analysis. *Am Surg* 2019;85:142–149.
9. Lewis SS, Moehring RW, Chen LF, Sexton DJ, Anderson DJ. Assessing the relative burden of hospital-acquired infections in a network of community hospitals. *Infect Control Hosp Epidemiol* 2013;34:1229–1230.
10. Magill SS, Edwards JR, Bamberg W, *et al.* Multistate point-prevalence survey of healthcare-associated infections. *N Engl J Med* 2014;370:1198–1208.
11. Zimlichman E, Henderson D, Tamir O, *et al.* Healthcare-associated infections: a meta-analysis of costs and financial impact on the US healthcare system. *JAMA Intern Med* 2013;173:2039–2046.
12. Meeks DW, Lally KP, Carrick MM, *et al.* Compliance with guidelines to prevent surgical site infections: as simple as 1-2-3? *Am J Surg* 2011;201:76–83.
13. Umscheid CA, Mitchell MD, Doshi JA, Agarwal R, Williams K, Brennan PJ. Estimating the proportion of healthcare-associated infections

- that are reasonably preventable and the related mortality and costs. *Infect Control Hosp Epidemiol* 2011;32:101–114.
14. Cruse P. Wound infection surveillance. *Rev Infect Dis* 1981;3:734–737.
 15. Cruse PJ, Foord R. The epidemiology of wound infection: a 10-year prospective study of 62,939 wounds. *Surg Clin N Am* 1980;60:27–40.
 16. Anderson DJ, Kaye KS, Chen LF, *et al*. Clinical and financial outcomes due to methicillin resistant *Staphylococcus aureus* surgical site infection: a multicenter matched-outcomes study. *PLoS One* 2009;4:e8305.
 17. Engemann JJ, Carmeli Y, Cosgrove SE, *et al*. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with *Staphylococcus aureus* surgical site infection. *Clin Infect Dis* 2003;36:592–598.
 18. Kirkland KB, Briggs JP, Trivette SL, Wilkinson WE, Sexton DJ. The impact of surgical site infections in the 1990s: attributable mortality, excess length of hospitalization, and extra costs. *Infect Control Hosp Epidemiol* 1999;20:725–730.
 19. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, 1999, Hospital Infection Control Practices Advisory Committee. *Infect Control Hosp Epidemiol* 1999;20:250–278.
 20. Apisarnthanarak A, Jones M, Waterman BM, Carroll CM, Bernardi R, Fraser VJ. Risk factors for spinal surgical site infections in a community hospital: a case-control study. *Infect Control Hosp Epidemiol* 2003;24:31–36.
 21. Boyce JM, Potter-Bynoe G, Dziobek L. Hospital reimbursement patterns among patients with surgical wound infections following open-heart surgery. *Infect Control Hosp Epidemiol* 1990;11:89–93.
 22. Bozic KJ, Katz P, Cisternas M, Ono L, Ries MD, Showstack J. Hospital resource utilization for primary and revision total hip arthroplasty. *J Bone Joint Surg Am* 2005;87:570–576.
 23. Coello R, Glenister H, Fereres J, *et al*. The cost of infection in surgical patients: a case-control study. *J Hosp Infect* 1993;25:239–250.
 24. Hollenbeak CS, Murphy DM, Koenig S, Woodward RS, Dunagan WC, Fraser VJ. The clinical and economic impact of deep chest surgical site infections following coronary artery bypass graft surgery. *Chest* 2000;118:397–402.
 25. VandenBergh MF, Kluytmans JA, van Hout BA, *et al*. Cost-effectiveness of perioperative mupirocin nasal ointment in cardiothoracic surgery. *Infect Control Hosp Epidemiol* 1996;17:786–792.
 26. Vegas AA, Jodra VM, Garcia ML. Nosocomial infection in surgery wards: a controlled study of increased duration of hospital stays and direct cost of hospitalization. *Eur J Epidemiol* 1993;9:504–510.
 27. Whitehouse JD, Friedman ND, Kirkland KB, Richardson WJ, Sexton DJ. The impact of surgical site infections following orthopedic surgery at a community hospital and a university hospital: adverse quality of life, excess length of stay, and extra cost. *Infect Control Hosp Epidemiol* 2002;23:183–189.
 28. Moolla MS, Reddy K, Fwemba I, *et al*. Bacterial infection, antibiotic use and COVID-19: lessons from the intensive care unit. *South African Med J Suid-Afrikaanse tydskrif vir geneeskunde* 2021;111:575–581.
 29. Shaaban RH, Yassine OG, Bedwani RN, Abu-Sheasha GA. Evaluation of the costing methodology of published studies estimating costs of surgical site infections: a systematic review. *Infect Control Hosp Epidemiol* 2022;43:898–914.
 30. Hasegawa T, Tashiro S, Mihara T, *et al*. Efficacy of surgical skin preparation with chlorhexidine in alcohol according to the concentration required to prevent surgical site infection: meta-analysis. *BJS Open* 2022;6.
 31. O'Hara LM, Thom KA, Preas MA. Update to the Centers for Disease Control and Prevention and the Healthcare Infection Control Practices Advisory Committee Guideline for the Prevention of Surgical Site Infection (2017): a summary, review, and strategies for implementation. *Am J Infect Control* 2018;46:602–609.
 32. Scott RD. The direct medical costs of healthcare-associated Infections in US hospitals and the benefits of prevention. Centers for Disease Control and Prevention website. http://www.cdc.gov/hai/pdfs/hai/scott_costpaper.pdf. Published 2009. Accessed December 14, 2013.
 33. Weiner-Lasting LM, Abner S, Edwards JR, *et al*. Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: summary of data reported to the National Healthcare Safety Network, 2015–2017. *Infect Control Hosp Epidemiol* 2020;41:1–18.
 34. The NHSN standardized infection ratio (SIR): a guide to the SIR. Centers for Disease Control and Prevention website. <https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/nhsn-sir-guide.pdf>. Published February 2021. Accessed March 30, 2023.
 35. National Health Safety Network. Surgical site infection (SSI) event, 2013. Centers for Disease Control and Prevention website. <http://www.cdc.gov/nhsn/PDFs/pscManual/9pscSSICurrent.pdf>. Published 2013. Accessed March 30, 2023.
 36. State HAI plans. Centers for Disease Control and Prevention website. <https://www.cdc.gov/nhsn/cms/index.html>. Accessed March 30, 2023.
 37. National Healthcare Safety Network. CMS Reporting Requirements. Centers for Disease Control and Prevention website. <https://www.cdc.gov/nhsn/cms/index.html>. Accessed March 30, 2023.
 38. State HAI plans, June 2020. Centers for Disease Control and Prevention website. <https://www.cdc.gov/hai/state-based/state-hai-plans.html>. Published 2020. Accessed March 30, 2023.
 39. Campwala I, Unsell K, Gupta S. A comparative analysis of surgical wound infection methods: predictive values of the CDC, ASEPSIS, and Southampton scoring systems in evaluating breast reconstruction surgical site infections. *Plast Surg (Oakv)* 2019;27:93–99.
 40. Ju MH, Ko CY, Hall BL, Bosk CL, Bilimoria KY, Wick EC. A comparison of 2 surgical site infection monitoring systems. *JAMA Surg* 2015;150:51–57.
 41. National Healthcare Safety Network. Toolkit for data quality checks for reporting facilities, 2021. Centers for Disease Control and Prevention website. <https://www.cdc.gov/nhsn/pdfs/validation/2021/2021-nhsn-iv-for-facilities-508.pdf>. Published 2021. Accessed March 30, 2023.
 42. National Healthcare Safety Network. NHSN data validation, June 2021. Centers for Disease Control and Prevention website. <https://www.cdc.gov/nhsn/validation/index.html>. Published 2021. Accessed March 30, 2023.
 43. National Healthcare Safety Network. Surgical site infection event (SSI), 2022. Centers for Disease Control and Prevention website. <https://www.cdc.gov/nhsn/pdfs/pscmanual/9pscSSICurrent.pdf>. Published 2022. Accessed March 30, 2023.
 44. Condon RE, Schulte WJ, Malangoni MA, Anderson-Teschendorf MJ. Effectiveness of a surgical wound surveillance program. *Arch Surg* 1983;118:303–307.
 45. Kerstein M, Flower M, Harkavy LM, Gross PA. Surveillance for postoperative wound infections: practical aspects. *Am Surg* 1978;44:210–214.
 46. Mead PB, Pories SE, Hall P, Vacek PM, Davis JH Jr, Gamelli RL. Decreasing the incidence of surgical wound infections: validation of a surveillance-notification program. *Arch Surg* 1986;121:458–461.
 47. Lober WB, Evans HL. Patient-generated health data in surgical site infection: changing clinical workflow and care delivery. *Surg Infect (Larchmt)* 2019;20:571–576.
 48. Baker C, Luce J, Chenoweth C, Friedman C. Comparison of case-finding methodologies for endometritis after cesarean section. *Am J Infect Control* 1995;23:27–33.
 49. Cardo DM, Falk PS, Mayhall CG. Validation of surgical wound surveillance. *Infect Control Hosp Epidemiol* 1993;14:211–215.
 50. Cho SY, Chung DR, Choi JR, *et al*. Validation of semiautomated surgical site infection surveillance using electronic screening algorithms in 38 surgery categories. *Infect Control Hosp Epidemiol* 2018;39:931–935.
 51. Ming DY, Chen LF, Miller BA, Anderson DJ. The impact of depth of infection and postdischarge surveillance on rate of surgical site infections in a network of community hospitals. *Infect Control Hosp Epidemiol* 2012;33:276–282.
 52. Chalfine A, Cautet D, Lin WC, *et al*. Highly sensitive and efficient computer-assisted system for routine surveillance for surgical site infection. *Infect Control Hosp Epidemiol* 2006;27:794–801.

53. Miner AL, Sands KE, Yokoe DS, *et al.* Enhanced identification of postoperative infections among outpatients. *Emerg Infect Dis* 2004;10:1931–1937.
54. Yokoe DS, Noskin GA, Cunningham SM, *et al.* Enhanced identification of postoperative infections among inpatients. *Emerg Infect Dis* 2004;10:1924–1930.
55. Calderwood MS, Kleinman K, Bratzler DW, *et al.* Use of Medicare claims to identify US hospitals with a high rate of surgical site infection after hip arthroplasty. *Infect Control Hosp Epidemiol* 2013;34:31–39.
56. Huang SS, Placzek H, Livingston J, *et al.* Use of Medicare claims to rank hospitals by surgical site infection risk following coronary artery bypass graft surgery. *Infect Control Hosp Epidemiol* 2011;32:775–783.
57. Haley VB, Van Antwerpen C, Tserenpuntsag B, *et al.* Use of administrative data in efficient auditing of hospital-acquired surgical site infections, New York State 2009–2010. *Infect Control Hosp Epidemiol* 2012;33:565–571.
58. van Rooden SM, Tacconelli E, Pujol M, *et al.* A framework to develop semiautomated surveillance of surgical site infections: an international multicenter study. *Infect Control Hosp Epidemiol* 2020;41:194–201.
59. Noorit P, Siribumrungwong B, Thakkinstian A. Clinical prediction score for superficial surgical site infection after appendectomy in adults with complicated appendicitis. *World J Emerg Surg* 2018;13:23.
60. Zhu Y, Simon GJ, Wick EC, *et al.* Applying machine learning across sites: external validation of a surgical site infection detection algorithm. *J Am Coll Surg* 2021;232:963–971.
61. Grundmeier RW, Xiao R, Ross RK, *et al.* Identifying surgical site infections in electronic health data using predictive models. *J Am Med Inform Assoc* 2018;25:1160–1166.
62. Yokoe DS, Avery TR, Platt R, Huang SS. Reporting surgical site infections following total hip and knee arthroplasty: impact of limiting surveillance to the operative hospital. *Clin Infect Dis* 2013;57:1282–1288.
63. National action plan to prevent health care-associated infections: Roadmap to elimination: ambulatory surgical centers. US Health and Human services website. http://www.hhs.gov/ash/initiatives/hai/ambulatory_surgical_centers.html. Published January 4, 2013. Accessed March 30, 2023.
64. Pop-Vicas A, Stern R, Osman F, Safdar N. Variability in infection surveillance methods and impact on surgical site infection rates. *Am J Infect Control* 2021;49:188–193.
65. Kent P, McDonald M, Harris O, Mason T, Spelman D. Postdischarge surgical wound infection surveillance in a provincial hospital: follow-up rates, validity of data and review of the literature. *ANZ J Surg* 2001;71:583–589.
66. Mannien J, Wille JC, Snoeren RL, van den Hof S. Impact of postdischarge surveillance on surgical site infection rates for several surgical procedures: results from the nosocomial surveillance network in The Netherlands. *Infect Control Hosp Epidemiol* 2006;27:809–816.
67. Sands K, Vineyard G, Platt R. Surgical site infections occurring after hospital discharge. *J Infect Dis* 1996;173:963–970.
68. Fields AC, Pradarelli JC, Itani KMF. Preventing surgical site infections: looking beyond the current guidelines. *JAMA* 2020;323:1087–1088.
69. Segreti J, Parvizi J, Berbari E, Ricks P, Berrios-Torres SI. Introduction to the Centers for Disease Control and Prevention and Healthcare Infection Control Practices Advisory Committee guideline for prevention of surgical site infection: prosthetic joint arthroplasty section. *Surg Infect (Larchmt)* 2017;18:394–400.
70. Ban KA, Minei JP, Laronga C, *et al.* American College of Surgeons and Surgical Infection Society: surgical site infection guidelines, 2016 update. *J Am Coll Surg* 2017;224:59–74.
71. World Health Organization. *Global Guidelines for the Prevention of Surgical Site Infection*. Geneva: WHO Guidelines Review Committee; 2018.
72. Munoz-Price LS, Bowdle A, Johnston BL, *et al.* Infection prevention in the operating room anesthesia work area. *Infect Control Hosp Epidemiol* 2019;40:1–17.
73. Bratzler DW, Dellinger EP, Olsen KM, *et al.* Clinical practice guidelines for antimicrobial prophylaxis in surgery. *Am J Health Syst Pharm* 2013;70:195–283.
74. Calderwood MS, Yokoe DS, Murphy MV, *et al.* Effectiveness of a multistate quality improvement campaign in reducing risk of surgical site infections following hip and knee arthroplasty. *BMJ Qual Saf* 2019;28:374–381.
75. Griffin FA. Reducing surgical complications. *Jt Comm J Qual Pat Saf* 2007;33:660–665.
76. A resource from the Institute of Healthcare Improvement, Institute for Health Care Improvement. Institute of Healthcare Improvement website. www.ihc.org. Published January 31, 2007. Accessed March 30, 2023.
77. Centers for Medicare & Medicaid Services. *Hospital Care Compare*. Website: <https://www.medicare.gov/care-compare/?providerType=Hospital>
78. Hospital quality initiative public reporting: Hospital Care Compare and Provider Data Catalog. Centers for Medicare & Medicaid Services website. <https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/HospitalCompare>. Updated October 2022. Accessed March 30, 2023.
79. Hospital-acquired condition reduction program. Centers for Medicare & Medicaid Services website. <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/HAC-Reduction-Program>. Updated August 2022. Accessed March 30, 2023.
80. The Hospital Value-Based Purchasing (VBP) Program. Centers for Medicare & Medicaid Services website. <https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/Value-Based-Programs/HVBP/Hospital-Value-Based-Purchasing>. Accessed March 30, 2023.
81. NHSN Educational Roadmaps: CDC, NCEZID, DHQP. Centers for Disease Control and Prevention website. <https://www.cdc.gov/nhsn/training/roadmap/index.html>. Updated February 23, 2022. Accessed March 30, 2023.
82. Clifford RJ, Newhart D, Laguio-Vila MR, Gutowski JL, Bronstein MZ, Lesho EP. Infection preventionist staffing levels and rates of 10 types of healthcare-associated infections: a 9-year ambidirectional observation. *Infect Control Hosp Epidemiol* 2022;43:1641–1646.
83. van Kasteren ME, Mannien J, Kullberg BJ, *et al.* Quality improvement of surgical prophylaxis in Dutch hospitals: evaluation of a multisite intervention by time-series analysis. *J Antimicrob Chemother* 2005;56:1094–1102.
84. Ahuja S, Peiffer-Smadja N, Peven K, *et al.* Use of feedback data to reduce surgical site infections and optimize antibiotic use in surgery: a systematic scoping review. *Ann Surg* 2022;275:e345–e352.
85. Johnson KM, Newman KL, Green PK, *et al.* Incidence and risk factors of postoperative mortality and morbidity after elective versus emergent abdominal surgery in a national sample of 8,193 patients with cirrhosis. *Ann Surg* 2021;274:e345–e354.
86. Schweon S. Stamping out surgical site infections. *RN* 2006;69:36–40.
87. Torpy JM, Burke A, Glass RM. JAMA patient page. Wound infections. *JAMA* 2005;294:2122.
88. Kanter G, Connelly NR, Fitzgerald J. A system and process redesign to improve perioperative antibiotic administration. *Anesth Analg* 2006;103:1517–1521.
89. Nair BG, Newman SF, Peterson GN, Wu WY, Schwid HA. Feedback mechanisms including real-time electronic alerts to achieve near 100% timely prophylactic antibiotic administration in surgical cases. *Anesth Analg* 2010;111:1293–1300.
90. Pestotnik SL, Classen DC, Evans RS, Burke JP. Implementing antibiotic practice guidelines through computer-assisted decision support: clinical and financial outcomes. *Ann Intern Med* 1996;124:884–890.
91. Webb AL, Flagg RL, Fink AS. Reducing surgical site infections through a multidisciplinary computerized process for preoperative prophylactic antibiotic administration. *Am J Surg* 2006;192:663–668.
92. Cato KD, Liu J, Cohen B, Larson E. Electronic surveillance of surgical site infections. *Surg Infect (Larchmt)* 2017;18:498–502.
93. Bratzler DW, Houck PM, *et al.* Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. *Clin Infect Dis* 2004;38:1706–1715.
94. Bratzler DW, Hunt DR. The surgical infection prevention and surgical care improvement projects: national initiatives to improve outcomes for patients having surgery. *Clin Infect Dis* 2006;43:322–330.

95. Steinberg JP, Braun BI, Hellinger WC, *et al*. Timing of antimicrobial prophylaxis and the risk of surgical site infections: results from the Trial to Reduce Antimicrobial Prophylaxis Errors. *Ann Surg* 2009; 250:10–16.
96. van Kasteren ME, Mannien J, Ott A, Kullberg BJ, de Boer AS, Gyssens IC. Antibiotic prophylaxis and the risk of surgical site infections following total hip arthroplasty: timely administration is the most important factor. *Clin Infect Dis* 2007;44:921–927.
97. Mackeen AD, Packard RE, Ota E, Berghella V, Baxter JK. Timing of intravenous prophylactic antibiotics for preventing postpartum infectious morbidity in women undergoing cesarean delivery. *Cochrane Database Syst Rev* 2014:CD009516.
98. Soriano A, Bori G, Garcia-Ramiro S, *et al*. Timing of antibiotic prophylaxis for primary total knee arthroplasty performed during ischemia. *Clin Infect Dis* 2008;46:1009–1014.
99. Beltran RJ, Kako H, Chovanec T, Ramesh A, Bissonnette B, Tobias JD. Penicillin allergy and surgical prophylaxis: cephalosporin cross-reactivity risk in a pediatric tertiary care center. *J Pediatr Surg* 2015;50:856–859.
100. Blumenthal KG, Ryan EE, Li Y, Lee H, Kuhlen JL, Shenoy ES. The impact of a reported penicillin allergy on surgical site infection risk. *Clin Infect Dis* 2018;66:329–336.
101. Lam PW, Tarighi P, Elligsen M, *et al*. Self-reported beta-lactam allergy and the risk of surgical site infection: a retrospective cohort study. *Infect Control Hosp Epidemiol* 2020;41:438–443.
102. de Jonge SW, Boldingh QJJ, Koch AH, *et al*. Timing of Preoperative Antibiotic Prophylaxis and Surgical Site Infection: TAPAS, an observational cohort study. *Ann Surg* 2021;274:e308–e314.
103. Takemoto RC, Lonner B, Andres T, *et al*. Appropriateness of twenty-four-hour antibiotic prophylaxis after spinal surgery in which a drain is utilized: a prospective randomized study. *J Bone Joint Surg Am* 2015;97:979–986.
104. Harbarth S, Samore MH, Lichtenberg D, Carmeli Y. Prolonged antibiotic prophylaxis after cardiovascular surgery and its effect on surgical site infections and antimicrobial resistance. *Circulation* 2000;101:2916–2921.
105. McDonald M, Grabsch E, Marshall C, Forbes A. Single- versus multiple-dose antimicrobial prophylaxis for major surgery: a systematic review. *Aust N Z J Surg* 1998;68:388–396.
106. Miranda D, Mermel LA, Dellinger EP. Perioperative antibiotic prophylaxis: surgeons as antimicrobial stewards. *J Am Coll Surg* 2020;231:766–768.
107. Branch-Elliman W, O'Brien W, Strymish J, Itani K, Wyatt C, Gupta K. Association of duration and type of surgical prophylaxis with antimicrobial-associated adverse events. *JAMA Surg* 2019;154:590–598.
108. Li T, Zhang H, Chan PK, Fung WC, Fu H, Chiu KY. Risk factors associated with surgical site infections following joint replacement surgery: a narrative review. *Arthroplasty* 2022;4:11.
109. Ahmadzia HK, Patel EM, Joshi D, *et al*. Obstetric surgical site infections: 2 grams compared with 3 grams of cefazolin in morbidly obese women. *Obstet Gynecol* 2015;126:708–715.
110. Swank ML, Wing DA, Nicolau DP, McNulty JA. Increased 3-gram cefazolin dosing for cesarean delivery prophylaxis in obese women. *Am J Obstet Gynecol* 2015;213:415 e1–e8.
111. Morris AJ, Roberts SA, Grae N, Frampton CM. Surgical site infection rate is higher following hip and knee arthroplasty when cefazolin is underdosed. *Am J Health Syst Pharm* 2020;77:434–440.
112. Salm L, Marti WR, Stekhoven DJ, *et al*. Impact of bodyweight-adjusted antimicrobial prophylaxis on surgical site infection rates. *BJS Open* 2021;5.
113. Benefield EC, Hagemann TM, Allen HC, *et al*. Vancomycin dosing and pharmacokinetics in postoperative pediatric cardiothoracic surgery patients. *J Pediatr Pharmacol Ther* 2016;21:66–74.
114. Bauer LA, Edwards WA, Dellinger EP, Simonowitz DA. Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. *Eur J Clin Pharmacol* 1983;24:643–647.
115. Rollins KE, Javanmard-Emamghissi H, Lobo DN. Impact of mechanical bowel preparation in elective colorectal surgery: a meta-analysis. *World J Gastroenterol* 2018;24:519–536.
116. Toh JWT, Phan K, Hitos K, *et al*. Association of mechanical bowel preparation and oral antibiotics before elective colorectal surgery with surgical site infection: a network meta-analysis. *JAMA Netw Open* 2018;1:e183226.
117. Rollins KE, Javanmard-Emamghissi H, Acheson AG, Lobo DN. The role of oral antibiotic preparation in elective colorectal surgery: a meta-analysis. *Ann Surg* 2019;270:43–58.
118. Woodfield JC, Clifford K, Schmidt B, Turner GA, Amer MA, McCall JL. Strategies for antibiotic administration for bowel preparation among patients undergoing elective colorectal surgery: a network meta-analysis. *JAMA Surg* 2022;157:34–41.
119. Espin Basany E, Solís-Peña A, Pellino G, *et al*. Preoperative oral antibiotics and surgical site infections in colon surgery (ORALEV): a multicentre, single-blind, pragmatic, randomised controlled trial. *Lancet Gastroenterol Hepatol* 2020;5:729–738.
120. Koskenvuo L, Lehtonen T, Koskensalo S, *et al*. Mechanical and oral antibiotic bowel preparation versus no bowel preparation for elective colectomy (MOBILE): a multicentre, randomised, parallel, single-blinded trial. *Lancet* 2019;394:840–848.
121. Rybakov E, Nagudov M, Sukhina M, Shelygin Y. Impact of oral antibiotic prophylaxis on surgical site infection after rectal surgery: results of randomized trial. *Int J Colorectal Dis* 2021;36:323–330.
122. Lee JH, Ahn BK, Ryu J, Lee KH. Mechanical bowel preparation combined with oral antibiotics in colorectal cancer surgery: a nationwide population-based study. *Int J Colorectal Dis* 2021;36:1929–1935.
123. Papp G, Saftics G, Szabó BE, *et al*. Systemic versus Oral and Systemic Antibiotic Prophylaxis (SOAP) study in colorectal surgery: prospective randomized multicentre trial. *Br J Surg* 2021;108:271–276.
124. Pop-Vicas A, Safdar N. Preoperative decolonization as a strategy to reduce surgical site infection. *Curr Infect Dis Rep* 2019;21:35.
125. Schweizer M, Perencevich E, McDanel J, *et al*. Effectiveness of a bundled intervention of decolonization and prophylaxis to decrease gram-positive surgical site infections after cardiac or orthopedic surgery: systematic review and meta-analysis. *BMJ* 2013;346:f2743.
126. Bode LG, Kluytmans JA, Wertheim HF, *et al*. Preventing surgical site infections in nasal carriers of *Staphylococcus aureus*. *N Engl J Med* 2010;362:9–17.
127. Bode LG, van Rijen MM, Wertheim HF, *et al*. Long-term mortality after rapid screening and decolonization of *Staphylococcus aureus* carriers: observational follow-up study of a randomized, placebo-controlled trial. *Ann Surg* 2016;263:511–515.
128. Schweizer ML, Chiang HY, Septimus E, *et al*. Association of a bundled intervention with surgical site infections among patients undergoing cardiac, hip, or knee surgery. *JAMA* 2015;313:2162–2171.
129. Kline SE, Sanstead EC, Johnson JR, Kulasingam SL. Cost-effectiveness of preoperative *Staphylococcus aureus* screening and decolonization. *Infect Control Hosp Epidemiol* 2018;39:1340–1346.
130. Stambough JB, Nam D, Warren DK, *et al*. Decreased hospital costs and surgical site infection incidence with a universal decolonization protocol in primary total joint arthroplasty. *J Arthroplasty* 2017;32:728–734.
131. Harbarth S, Fankhauser C, Schrenzel J, *et al*. Universal screening for methicillin-resistant *Staphylococcus aureus* at hospital admission and nosocomial infection in surgical patients. *JAMA* 2008;299:1149–1157.
132. Lee AS, Cooper BS, Malhotra-Kumar S, *et al*. Comparison of strategies to reduce methicillin-resistant *Staphylococcus aureus* rates in surgical patients: a controlled multicentre intervention trial. *BMJ Open* 2013;3:e003126.
133. Lee AS, Cooper BS, Malhotra-Kumar S, *et al*. Comparison of strategies to reduce methicillin-resistant *Staphylococcus aureus* rates in surgical patients: a controlled multicentre intervention trial. *BMJ Open* 2013;3:e003126.
134. Perl TM, Cullen JJ, Wenzel RP, *et al*. Intranasal mupirocin to prevent postoperative *Staphylococcus aureus* infections. *N Engl J Med* 2002;346:1871–1877.
135. van Rijen M, Bonten M, Wenzel R, Kluytmans J. Mupirocin ointment for preventing *Staphylococcus aureus* infections in nasal carriers. *Cochrane Database Syst Rev* 2008:CD006216.
136. Miller MA, Dascal A, Portnoy J, Mendelson J. Development of mupirocin resistance among methicillin-resistant *Staphylococcus aureus* after widespread use of nasal mupirocin ointment. *Infect Control Hosp Epidemiol* 1996;17:811–813.
137. Phillips M, Rosenberg A, Shopsin B, *et al*. Preventing surgical site infections: a randomized, open-label trial of nasal mupirocin ointment and

- nasal povidone-iodine solution. *Infect Control Hosp Epidemiol* 2014;35:826–832.
138. Bebeko SP, Green DM, Awad SS. Effect of a preoperative decontamination protocol on surgical site infections in patients undergoing elective orthopedic surgery with hardware implantation. *JAMA Surg* 2015;150:390–395.
 139. Urias DS, Varghese M, Simunich T, Morrissey S, Dumire R. Preoperative decolonization to reduce infections in urgent lower extremity repairs. *Eur J Trauma Emerg Surg* 2018;44:787–793.
 140. Kaul AF, Jewett JF. Agents and techniques for disinfection of the skin. *Surg Gynecol Obstet* 1981;152:677–685.
 141. Moores N, Rosenblatt S, Prabhu A, Rosen M. Do iodine-impregnated adhesive surgical drapes reduce surgical site infections during open ventral hernia repair? A comparative analysis. *Am Surg* 2017;83:617–622.
 142. Webster J, Osborne S. Preoperative bathing or showering with skin antiseptics to prevent surgical site infection. *Cochrane Database Syst Rev* 2007;CD004985.
 143. Edmiston CE, Jr., Krepel CJ, Seabrook GR, Lewis BD, Brown KR, Towne JB. Preoperative shower revisited: can high topical antiseptic levels be achieved on the skin surface before surgical admission? *J Am Coll Surg* 2008;207:233–239.
 144. Eiselt D. Presurgical skin preparation with a novel 2% chlorhexidine gluconate cloth reduces rates of surgical site infection in orthopaedic surgical patients. *Orthoped Nurs* 2009;28:141–145.
 145. Rhee Y, Palmer LJ, Okamoto K, et al. Differential effects of chlorhexidine skin cleansing methods on residual chlorhexidine skin concentrations and bacterial recovery. *Infect Control Hosp Epidemiol* 2018;39:405–411.
 146. Haas DM, Morgan S, Contreras K, Kimball S. Vaginal preparation with antiseptic solution before cesarean section for preventing postoperative infections. *Cochrane Database Syst Rev* 2020;4:CD007892.
 147. Hill AM, Pauls RN, Basil J, et al. Chlorhexidine versus iodine for vaginal preparation before hysterectomy: a randomized clinical trial. *Female Pelvic Med Reconstr Surg* 2022;28:77–84.
 148. Grober ED, Domes T, Fanipour M, Copp JE. Preoperative hair removal on the male genitalia: clippers vs. razors. *J Sex Med* 2013;10:589–594.
 149. Maiwald M, Chan ES. The forgotten role of alcohol: a systematic review and meta-analysis of the clinical efficacy and perceived role of chlorhexidine in skin antiseptics. *PLoS One* 2012;7:e44277.
 150. Dumville JC, McFarlane E, Edwards P, Lipp A, Holmes A, Liu Z. Preoperative skin antiseptics for preventing surgical wound infections after clean surgery. *Cochrane Database Syst Rev* 2015;4:CD003949.
 151. Tuuli MG, Liu J, Stout MJ, et al. A randomized trial comparing skin antiseptic agents at cesarean delivery. *N Engl J Med* 2016;374:647–655.
 152. Ritter B, Herlyn PKE, Mittlmeier T, Herlyn A. Preoperative skin antiseptics using chlorhexidine may reduce surgical wound infections in lower limb trauma surgery when compared to povidone-iodine—a prospective randomized trial. *Am J Infect Control* 2020;48:167–172.
 153. Broach RB, Paulson EC, Scott C, Mahmoud NN. Randomized controlled trial of two alcohol-based preparations for surgical site antiseptics in colorectal surgery. *Ann Surg* 2017;266:946–951.
 154. Charehbili A, Koek MBG, de Mol van Otterloo JCA, et al. Cluster-randomized crossover trial of chlorhexidine-alcohol versus iodine-alcohol for prevention of surgical site infection (SKINFECT trial). *BJS Open* 2019;3:617–622.
 155. Aho Glele LS, Ortega-Deballon P, Guilloteau A, Keita-Perse O, Astruc K, Lepelletier D. Cluster-randomized crossover trial of chlorhexidine-alcohol versus iodine-alcohol for prevention of surgical site infection (SKINFECT trial). *BJS Open* 2020;4:731–733.
 156. Aly R, Maibach HI. Comparative antibacterial efficacy of a 2-minute surgical scrub with chlorhexidine gluconate, povidone-iodine, and chloroxylenol sponge brushes. *Am J Infect Control* 1988;16:173–177.
 157. Larson E. Guideline for use of topical antimicrobial agents. *Am J Infect Control* 1988;16:253–266.
 158. Chapman AK, Aucott SW, Milstone AM. Safety of chlorhexidine gluconate used for skin antiseptics in the preterm infant. *J Perinatol* 2012;32:4–9.
 159. Carr S, Gogal C, Afshar K, Ting J, Skarsgard E. Optimizing skin antiseptics for neonatal surgery: a quality improvement initiative. *J Pediatr Surg* 2022;57:1235–1241.
 160. Dramowski A, Pillay S, Bekker A, et al. Impact of 1% chlorhexidine gluconate bathing and emollient application on bacterial pathogen colonization dynamics in hospitalized preterm neonates—a pilot clinical trial. *EClinicalMedicine* 2021;37:100946.
 161. Jain A, Deshpande P, Yoon EW, Lee KS, McGeer A, Shah V. 2% aqueous vs alcohol-based chlorhexidine for skin antiseptics in VLBW neonates undergoing peripheral venipuncture: a noninferiority trial. *J Perinatol* 2022;42:636–641.
 162. Sharma A, Kulkarni S, Thukral A, et al. Aqueous chlorhexidine 1% versus 2% for neonatal skin antiseptics: a randomised noninferiority trial. *Arch Dis Child Fetal Neonatal Ed* 2021;106:643–648.
 163. Sessler DI. Complications and treatment of mild hypothermia. *Anesthesiology* 2001;95:531–543.
 164. Kurz A, Sessler DI, Lenhardt R. Perioperative normothermia to reduce the incidence of surgical wound infection and shorten hospitalization, Study of Wound Infection and Temperature Group. *N Engl J Med* 1996;334:1209–1215.
 165. Melling AC, Ali B, Scott EM, Leaper DJ. Effects of preoperative warming on the incidence of wound infection after clean surgery: a randomised controlled trial. *Lancet* 2001;358:876–880.
 166. Wong PF, Kumar S, Bohra A, Whetter D, Leaper DJ. Randomized clinical trial of perioperative systemic warming in major elective abdominal surgery. *Br J Surg* 2007;94:421–426.
 167. Zheng XQ, Huang JF, Lin JL, Chen D, Wu AM. Effects of preoperative warming on the occurrence of surgical site infection: a systematic review and meta-analysis. *Int J Surg* 2020;77:40–47.
 168. Lau A, Lowlaavar N, Cooke EM, et al. Effect of preoperative warming on intraoperative hypothermia: a randomized-controlled trial. *Can J Anaesth* 2018;65:1029–1040.
 169. Kang SI, Oh HK, Kim MH, et al. Systematic review and meta-analysis of randomized controlled trials of the clinical effectiveness of impervious plastic wound protectors in reducing surgical site infections in patients undergoing abdominal surgery. *Surgery* 2018;164:939–945.
 170. Bressan AK, Aubin JM, Martel G, et al. Efficacy of a dual-ring wound protector for prevention of surgical site infections after pancreaticoduodenectomy in patients with intrabiliary stents: a randomized clinical trial. *Ann Surg* 2018;268:35–40.
 171. Whiteside OJ, Tytherleigh MG, Thrush S, Farouk R, Galland RB. Intraoperative peritoneal lavage—who does it and why? *Ann R Coll Surg Engl* 2005;87:255–258.
 172. Ambe PC, Rombey T, Rembe JD, Dorner J, Zirngibl H, Pieper D. The role of saline irrigation prior to wound closure in the reduction of surgical site infection: a systematic review and meta-analysis. *Patient Saf Surg* 2020;14:47.
 173. Norman G, Atkinson RA, Smith TA, et al. Intracavity lavage and wound irrigation for prevention of surgical site infection. *Cochrane Database Syst Rev* 2017;10:CD012234.
 174. Mueller TC, Loos M, Haller B, et al. Intraoperative wound irrigation to reduce surgical site infections after abdominal surgery: a systematic review and meta-analysis. *Langenbecks Arch Surg* 2015;400:167–181.
 175. Thom H, Norman G, Welton NJ, Crosbie EJ, Blazeby J, Dumville JC. Intracavity lavage and wound irrigation for prevention of surgical site infection: systematic review and network meta-analysis. *Surg Infect (Larchmt)* 2021;22:144–167.
 176. Lopez-Cano M, Kraft M, Curell A, et al. Use of topical antibiotics before primary incision closure to prevent surgical site infection: a meta-analysis. *Surg Infect (Larchmt)* 2019;20:261–270.
 177. FDA requests withdrawal of bacitracin for injection from market, January 31, 2020. US Food and Drug Administration website. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-withdrawal-bacitracin-injection-market>. Published January 31, 2020. Accessed March 30, 2023.
 178. Strobel RM, Leonhardt M, Krochmann A, et al. Reduction of Postoperative Wound Infections by Antiseptics (RECIPE)? a randomized controlled trial. *Ann Surg* 2020;272:55–64.
 179. De Santo LS, Rubino AS, Torella M, et al. Topical rifampicin for prevention of deep sternal wound infections in patients undergoing coronary artery bypass grafting. *Sci Rep* 2020;10:7400.

180. Kwon S, Thompson R, Dellinger P, Yanez D, Farrohi E, Flum D. Importance of perioperative glycemic control in general surgery: a report from the Surgical Care and Outcomes Assessment Program. *Ann Surg* 2013;257:8–14.
181. Dronge AS, Perkal MF, Kancir S, Concato J, Aslan M, Rosenthal RA. Long-term glycemic control and postoperative infectious complications. *Arch Surg* 2006;141:375–380.
182. Golden SH, Peart-Vigilance C, Kao WH, Brancati FL. Perioperative glycemic control and the risk of infectious complications in a cohort of adults with diabetes. *Diabetes Care* 1999;22:1408–1414.
183. Olsen MA, Lefta M, Dietz JR, *et al*. Risk factors for surgical site infection after major breast operation. *J Am Coll Surg* 2008;207:326–335.
184. Umpierrez GE, Smiley D, Jacobs S, *et al*. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). *Diabetes Care* 2011;34:256–261.
185. Wang Y-Y, Hu S-F, Ying H-M, *et al*. Postoperative tight glycemic control significantly reduces postoperative infection rates in patients undergoing surgery: a meta-analysis. *BMC Endocr Disord* 2018;18:42.
186. Ogawa S, Okawa Y, Sawada K, *et al*. Continuous postoperative insulin infusion reduces deep sternal wound infection in patients with diabetes undergoing coronary artery bypass grafting using bilateral internal mammary artery grafts: a propensity-matched analysis. *Eur J Cardiothorac Surg* 2016;49:420–426.
187. Okabayashi T, Shima Y, Sumiyoshi T, *et al*. Intensive versus intermediate glucose control in surgical intensive care unit patients. *Diabetes Care* 2014;37:1516–1524.
188. Al-Niaimi AN, Ahmed M, Burish N, *et al*. Intensive postoperative glucose control reduces the surgical site infection rates in gynecologic oncology patients. *Gynecol Oncol* 2015;136:71–76.
189. WHO surgical safety checklist. World Health Organization website. <https://www.who.int/teams/integrated-health-services/patient-safety/research/safe-surgery/tool-and-resources>. Accessed March 30, 2023.
190. Haynes AB, Weiser TG, Berry WR, *et al*. A surgical safety checklist to reduce morbidity and mortality in a global population. *N Engl J Med* 2009;360:491–499.
191. van Klei WA, Hoff RG, van Aarnhem EE, *et al*. Effects of the introduction of the WHO “Surgical Safety Checklist” on in-hospital mortality: a cohort study. *Ann Surg* 2012;255:44–49.
192. Weiser TG, Haynes AB, Dziekan G, *et al*. Effect of a 19-item surgical safety checklist during urgent operations in a global patient population. *Ann Surg* 2010;251:976–980.
193. Pop-Vicas AE, Abad C, Baubie K, Osman F, Heise C, Safdar N. Colorectal bundles for surgical site infection prevention: a systematic review and meta-analysis. *Infect Control Hosp Epidemiol* 2020;41:805–812.
194. Lee JT. Wound infection surveillance. *Infect Dis Clin N Am* 1992;6:643–656.
195. Dellinger EP, Villaflor-Camagong D, Whimbey E. Gradually increasing surgical site infection prevention bundle with monitoring of potentially preventable infections resulting in decreasing overall surgical site infection rate. *Surg Infect (Larchmt)* 2021;22:1072–1076.
196. Bolon MK, Hooper D, Stevenson KB, *et al*. Improved surveillance for surgical site infections after orthopedic implantation procedures: extending applications for automated data. *Clin Infect Dis* 2009;48:1223–1229.
197. Calderwood MS, Ma A, Khan YM, *et al*. Use of Medicare diagnosis and procedure codes to improve detection of surgical site infections following hip arthroplasty, knee arthroplasty, and vascular surgery. *Infect Control Hosp Epidemiol* 2012;33:40–49.
198. Gerbier-Colomban S, Bourjault M, Cetre JC, Baulieux J, Metzger MH. Evaluation study of different strategies for detecting surgical site infections using the hospital information system at Lyon University Hospital, France. *Ann Surg* 2012;255:896–900.
199. Yokoe DS, Khan Y, Olsen MA, *et al*. Enhanced surgical site infection surveillance following hysterectomy, vascular, and colorectal surgery. *Infect Control Hosp Epidemiol* 2012;33:768–773.
200. Jamtvedt G, Young JM, Kristoffersen DT, O’Brien MA, Oxman AD. Audit and feedback: effects on professional practice and health care outcomes. *Cochrane Database Syst Rev* 2006:CD000259.
201. National surgical quality improvement. American College of Surgeons website. <https://www.facs.org/quality-programs/data-and-registries/acs-nsqip>. Accessed March 30, 2023.
202. Skoufalos A, Clarke JL, Napp M, *et al*. Improving awareness of best practices to reduce surgical site infection: a multistakeholder approach. *Am J Med Qual* 2012;27:297–304.
203. Tips for safer surgery. Institute for Health Care Improvement website. <https://www.ihc.org/resources/Pages/Tools/TipsforSaferSurgery.aspx>. Accessed March 30, 2023.
204. Frequently asked questions about surgical site infections, May 2019. Centers for Disease Control and Prevention website. https://www.cdc.gov/hai/ssi/faq_ssi.html. Published 2019. Accessed March 30, 2023.
205. For our patients and their visitors: help prevent infections. Society for Healthcare Epidemiology of America website. www.shea-online.org. Accessed March 30, 2023.
206. Loftus RW, Brown JR, Koff MD, *et al*. Multiple reservoirs contribute to intraoperative bacterial transmission. *Anesth Analg* 2012;114:1236–1248.
207. Andersson AE, Bergh I, Karlsson J, Eriksson BI, Nilsson K. Traffic flow in the operating room: an explorative and descriptive study on air quality during orthopedic trauma implant surgery. *Am J Infect Control* 2012;40:750–755.
208. Crolla RM, van der Laan L, Veen EJ, Hendriks Y, van Schendel C, Kluytmans J. Reduction of surgical site infections after implementation of a bundle of care. *PLoS One* 2012;7:e44599.
209. Marra AR, Diekema DJ, Edmond MB. Successful termination of an outbreak of *Mycobacterium chimaera* infections associated with contaminated heater-cooler devices. *Infect Control Hosp Epidemiol* 2021;42:471–473.
210. van Ingen J, Kohl TA, Kranzer K, *et al*. Global outbreak of severe *Mycobacterium chimaera* disease after cardiac surgery: a molecular epidemiological study. *Lancet Infect Dis* 2017;17:1033–41.
211. Haessler S, Connelly NR, Kanter G, *et al*. A surgical site infection cluster: the process and outcome of an investigation—the impact of an alcohol-based surgical antiseptic product and human behavior. *Anesth Analg* 2010;110:1044–1048.
212. Panahi P, Stroh M, Casper DS, Parvizi J, Austin MS. Operating room traffic is a major concern during total joint arthroplasty. *Clin Orthop Relat Res* 2012;470:2690–2694.
213. Tadros MA, Williams VR, Plourde S, Callery S, Simor AE, Vearncombe M. Risk factors for *Staphylococcus aureus* surgical site infection during an outbreak in patients undergoing cardiovascular surgery. *Am J Infect Control* 2013;41:509–512.
214. Wiener-Well Y, Galuty M, Rudensky B, Schlesinger Y, Attias D, Yinnon AM. Nursing and physician attire as possible source of nosocomial infections. *Am J Infect Control* 2011;39:555–559.
215. Wright MO, Tropp J, Schora DM, *et al*. Continuous passive disinfection of catheter hubs prevents contamination and bloodstream infection. *Am J Infect Control* 2013;41:33–38.
216. Thompson KM, Oldenburg WA, Deschamps C, Rupp WC, Smith CD. Chasing zero: the drive to eliminate surgical site infections. *Ann Surg* 2011;254:430–436.
217. De Vries FEE, Wallert ED, Solomkin JS, *et al*. A systematic review and meta-analysis including GRADE qualification of the risk of surgical site infections after prophylactic negative pressure wound therapy compared with conventional dressings in clean and contaminated surgery. *Medicine (Baltimore)* 2016;95:e4673.
218. Norman G, Goh EL, Dumville JC, *et al*. Negative pressure wound therapy for surgical wounds healing by primary closure. *Cochrane Database Syst Rev* 2020;6:CD009261.
219. Zwanenburg PR, Tol BT, Obdeijn MC, Lapid O, Gans SL, Boermeester MA. Meta-analysis, Meta-regression, and GRADE Assessment of Randomized and Nonrandomized Studies of Incisional Negative

- Pressure Wound Therapy Versus Control Dressings for the Prevention of Postoperative Wound Complications. *Ann Surg* 2020;272:81–91.
220. Fowler AL, Barry MK. Closed incision negative pressure therapy: results of recent trials and recommendations for clinical practice. *Surgeon*. 2020;18:241–250.
 221. Meyer J, Roos E, Abbassi Z, Buchs NC, Ris F, Toso C. Prophylactic negative-pressure wound therapy prevents surgical site infection in abdominal surgery: an updated systematic review and meta-analysis of randomized controlled trials and observational studies. *Clin Infect Dis* 2020.
 222. Ailaney N, Johns WL, Golladay GJ, Strong B, Kalore NV. Closed incision negative pressure wound therapy for elective hip and knee arthroplasty: a systematic review and meta-analysis of randomized controlled trials. *J Arthroplasty* 2021;36:2402–2411.
 223. Higuera-Rueda CA, Emara AK, Nieves-Malloure Y, et al. The effectiveness of closed-incision negative-pressure therapy versus silver-impregnated dressings in mitigating surgical site complications in high-risk patients after revision knee arthroplasty: the PROMISES randomized controlled trial. *J Arthroplasty* 2021;36:S295–S302.
 224. Almansa-Saura S, Lopez-Lopez V, Eshmunov D, et al. Prophylactic use of negative pressure therapy in general abdominal surgery: a systematic review and meta-analysis. *Surg Infect (Larchmt)* 2021;22:854–863.
 225. Saunders C, Nherera LM, Horner A, Trueman P. Single-use negative-pressure wound therapy versus conventional dressings for closed surgical incisions: systematic literature review and meta-analysis. *BJS Open* 2021;5:zraa003.
 226. Wells CI, Ratnayake CBB, Perrin J, Pandanaboyana S. Prophylactic negative-pressure wound therapy in closed abdominal incisions: a meta-analysis of randomised controlled trials. *World J Surg* 2019;43:2779–2788.
 227. Kohlenberg A, Weitzel-Kage D, van der Linden P, et al. Outbreak of carbapenem-resistant *Pseudomonas aeruginosa* infection in a surgical intensive care unit. *J Hosp Infect* 2010;74:350–357.
 228. Elek SD, Conen PE. The virulence of *Staphylococcus pyogenes* for man; a study of the problems of wound infection. *Br J Exp Pathol* 1957; 38:573–586.
 229. Olmez T, Berkesoglu M, Turkmenoglu O, Colak T. Effect of triclosan-coated suture on surgical site infection of abdominal fascial closures. *Surg Infect (Larchmt)* 2019;20:658–664.
 230. Ruiz-Tovar J, Llavero C, Jimenez-Fuertes M, Duran M, Perez-Lopez M, Garcia-Marin A. Incisional surgical site infection after abdominal fascial closure with triclosan-coated barbed suture vs triclosan-coated polydioxanone loop suture vs polydioxanone loop suture in emergent abdominal surgery: a randomized clinical trial. *J Am Coll Surg* 2020;230:766–774.
 231. Nakamura T, Kashimura N, Noji T, Suzuki O, Ambo Y, Nakamura F, et al. Triclosan-coated sutures reduce the incidence of wound infections and the costs after colorectal surgery: a randomized controlled trial. *Surgery* 2013;153:576–583.
 232. Chang WK, Srinivasa S, Morton R, Hill AG. Triclosan-impregnated sutures to decrease surgical site infections: systematic review and meta-analysis of randomized trials. *Ann Surg* 2012;255:854–859.
 233. Deliaert AE, Van den Kerckhove E, Tuinder S, et al. The effect of triclosan-coated sutures in wound healing: a double-blind randomised prospective pilot study. *J Plast Reconstr Aesthet Surg* 2009;62:771–773.
 234. Murphy E, Spencer SJ, Young D, Jones B, Blyth MJ. MRSA colonisation and subsequent risk of infection despite effective eradication in orthopaedic elective surgery. *J Bone Joint Surg Br* 2011;93:548–551.
 235. Dodds Ashley ES, Carroll DN, Engemann JJ, et al. Risk factors for post-operative mediastinitis due to methicillin-resistant *Staphylococcus aureus*. *Clin Infect Dis* 2004;38:1555–1560.
 236. Strymish J, Branch-Elliman W, Itani KM, Williams S, Gupta K. A clinical history of methicillin-resistant *Staphylococcus aureus* is a poor predictor of preoperative colonization status and postoperative infections. *Infect Control Hosp Epidemiol* 2012;33:1113–1117.
 237. Bolon MK, Morlote M, Weber SG, Koplan B, Carmeli Y, Wright SB. Glycopeptides are no more effective than beta-lactam agents for prevention of surgical site infection after cardiac surgery: a meta-analysis. *Clin Infect Dis* 2004;38:1357–1363.
 238. Bull AL, Worth LJ, Richards MJ. Impact of vancomycin surgical antibiotic prophylaxis on the development of methicillin-sensitive staphylococcus aureus surgical site infections: report from Australian Surveillance Data (VICNISS). *Ann Surg* 2012;256:1089–1092.
 239. Chambers D, Worthy G, Myers L, et al. Glycopeptide vs nonglycopeptide antibiotics for prophylaxis of surgical site infections: a systematic review. *Surg Infect (Larchmt)* 2010;11:455–462.
 240. Balch A, Wendelboe AM, Vesely SK, Bratzler DW. Antibiotic prophylaxis for surgical site infections as a risk factor for infection with *Clostridium difficile*. *PLoS One* 2017;12:e0179117.
 241. Branch-Elliman W, Ripollone JE, O'Brien WJ, et al. Risk of surgical site infection, acute kidney injury, and *Clostridium difficile* infection following antibiotic prophylaxis with vancomycin plus a beta-lactam versus either drug alone: a national propensity-score-adjusted retrospective cohort study. *PLoS Med* 2017;14:e1002340.
 242. Brennan MF, Pisters PW, Posner M, Quesada O, Shike M. A prospective randomized trial of total parenteral nutrition after major pancreatic resection for malignancy. *Ann Surg* 1994;220:436–441.
 243. Veterans' Affairs Total Parenteral Nutrition Cooperative Study Group. Perioperative total parenteral nutrition in surgical patients. *N Engl J Med* 1991;325:525–532.
 244. Marimuthu K, Varadhan KK, Ljungqvist O, Lobo DN. A meta-analysis of the effect of combinations of immune modulating nutrients on outcome in patients undergoing major open gastrointestinal surgery. *Ann Surg* 2012;255:1060–1068.
 245. Zhang Y, Gu Y, Guo T, Li Y, Cai H. Perioperative immunonutrition for gastrointestinal cancer: a systematic review of randomized controlled trials. *Surg Oncol* 2012;21:e87–e95.
 246. Webster J, Alghamdi AA. Use of plastic adhesive drapes during surgery for preventing surgical site infection. *Cochrane Database Syst Rev* 2007; CD006353.
 247. Dewan PA, Van Rij AM, Robinson RG, Skeggs GB, Fergus M. The use of an iodophor-impregnated plastic incise drape in abdominal surgery—a controlled clinical trial. *Aust N Z J Surg* 1987;57:859–863.
 248. Segal CG, Anderson JJ. Preoperative skin preparation of cardiac patients. *AORN J* 2002;76:821–828.
 249. Swenson BR, Camp TR, Mulloy DP, Sawyer RG. Antimicrobial-impregnated surgical incise drapes in the prevention of mesh infection after ventral hernia repair. *Surg Infect (Larchmt)* 2008;9:23–32.
 250. Wetterslev J, Meyhoff CS, Jorgensen LN, Gluud C, Lindschou J, Rasmussen LS. The effects of high perioperative inspiratory oxygen fraction for adult surgical patients. *Cochrane Database Syst Rev* 2015; CD008884.
 251. Ferrando C, Aldecoa C, Unzueta C, et al. Effects of oxygen on postsurgical infections during an individualised perioperative open-lung ventilatory strategy: a randomised controlled trial. *Br J Anaesth* 2020; 124:110–120.
 252. Shaffer SK, Tubog TD, Kane TD, Stortroen NE. Supplemental oxygen and surgical site infection in colorectal surgery: a systematic review and meta-analysis. *AANA J* 2021;89:245–253.
 253. Smith BK, Roberts RH, Frizelle FA. O(2) no longer the go(2): a systematic review and meta-analysis comparing the effects of giving perioperative oxygen therapy of 30% FiO(2) to 80% FiO(2) on surgical site infection and mortality. *World J Surg* 2020;44:69–77.
 254. Belda FJ, Aguilera L, Garcia de la Asuncion J, et al. Supplemental perioperative oxygen and the risk of surgical wound infection: a randomized controlled trial. *JAMA* 2005;294:2035–2042.
 255. Bickel A, Gurevits M, Vamos R, Ivry S, Eitan A. Perioperative hyperoxygenation and wound site infection following surgery for acute appendicitis: a randomized, prospective, controlled trial. *Arch Surg* 2011;146: 464–470.
 256. Greif R, Akca O, Horn EP, Kurz A, Sessler DI, Outcomes Research G. Supplemental perioperative oxygen to reduce the incidence of surgical wound infection. *N Engl J Med* 2000;342:161–167.
 257. Segers P, Speekenbrink RG, Ubbink DT, van Ogtrop ML, de Mol BA. Prevention of nosocomial infection in cardiac surgery by decontamination of the nasopharynx and oropharynx with chlorhexidine gluconate: a randomized controlled trial. *JAMA* 2006;296:2460–2466.
 258. de Bruin AF, Gosselink MP, van der Harst E, Rutten HJ. Local application of gentamicin collagen implants in the prophylaxis of surgical site

- infections following gastrointestinal surgery: a review of clinical experience. *Tech Coloproctol* 2010;14:301–310.
259. Guzman Valdivia Gomez G, Guerrero TS, Lluck MC, Delgado FJ. Effectiveness of collagen-gentamicin implant for treatment of “dirty” abdominal wounds. *World J Surg* 1999;23:123–126.
 260. Rutten HJ, Nijhuis PH. Prevention of wound infection in elective colorectal surgery by local application of a gentamicin-containing collagen sponge. *Eur J Surg Suppl* 1997;31–35.
 261. Bennett-Guerrero E, Berry SM, Bergese SD, *et al*. A randomized, blinded, multicenter trial of a gentamicin vancomycin gel (DFA-02) in patients undergoing abdominal surgery. *Am J Surg* 2017;213:1003–1009.
 262. Bennett-Guerrero E, Pappas TN, Koltun WA, *et al*. Gentamicin-collagen sponge for infection prophylaxis in colorectal surgery. *N Engl J Med* 2010;363:1038–1049.
 263. Bennett-Guerrero E, Ferguson TB Jr, Lin M, *et al*. Effect of an implantable gentamicin-collagen sponge on sternal wound infections following cardiac surgery: a randomized trial. *JAMA* 2010;304:755–762.
 264. Eklund AM, Valtonen M, Werkkala KA. Prophylaxis of sternal wound infections with gentamicin-collagen implant: randomized controlled study in cardiac surgery. *J Hosp Infect* 2005;59:108–112.
 265. Friberg O, Svedjeholm R, Soderquist B, Granfeldt H, Vikerfors T, Kallman J. Local gentamicin reduces sternal wound infections after cardiac surgery: a randomized controlled trial. *Ann Thorac Surg* 2005;79:153–161.
 266. Schimmer C, Ozkur M, Sinha B, *et al*. Gentamicin-collagen sponge reduces sternal wound complications after heart surgery: a controlled, prospectively randomized, double-blind study. *J Thorac Cardiovasc Surg* 2012;143:194–200.
 267. Kowalewski M, Pawlitzak W, Zaborowska K, *et al*. Gentamicin-collagen sponge reduces the risk of sternal wound infections after heart surgery: meta-analysis. *J Thorac Cardiovasc Surg* 2015;149:1631–1640.
 268. Ravikumar V, Ho AL, Pendhakar AV, Sussman ES, Kwong-Hon Chow K, Li G. The use of vancomycin powder for surgical prophylaxis following craniotomy. *Neurosurgery* 2017;80:754–758.
 269. Haimoto S, Schar RT, Nishimura Y, Hara M, Wakabayashi T, Ginsberg HJ. Reduction in surgical site infection with suprafascial intrawound application of vancomycin powder in instrumented posterior spinal fusion: a retrospective case-control study. *J Neurosurg Spine* 2018;29:193–198.
 270. McCutcheon BA, Ubl DS, Babu M, *et al*. Predictors of surgical site infection following craniotomy for intracranial neoplasms: an analysis of prospectively collected data in the American College of Surgeons National Surgical Quality Improvement Program Database. *World Neurosurg* 2016;88:350–358.
 271. Adogwa O, Elsamadicy AA, Sergesketter A, *et al*. Prophylactic use of intraoperative vancomycin powder and postoperative infection: an analysis of microbiological patterns in 1,200 consecutive surgical cases. *J Neurosurg Spine* 2017;27:328–334.
 272. Grabel ZJ, Boden A, Segal DN, Boden S, Milby AH, Heller JG. The impact of prophylactic intraoperative vancomycin powder on microbial profile, antibiotic regimen, length of stay, and reoperation rate in elective spine surgery. *Spine J* 2019;19:261–266.
 273. Gande A, Rosinski A, Cunningham T, Bhatia N, Lee YP. Selection pressures of vancomycin powder use in spine surgery: a meta-analysis. *Spine J* 2019;19:1076–1084.
 274. Tubaki VR, Rajasekaran S, Shetty AP. Effects of using intravenous antibiotic only versus local intrawound vancomycin antibiotic powder application in addition to intravenous antibiotics on postoperative infection in spine surgery in 907 patients. *Spine (Phila Pa 1976)* 2013;38:2149–2155.
 275. A statement from the meeting of ACS, AORN, ASA, APIC, AST, and TJC concerning recommendations for operating room attire. American College of Surgeons website. <https://www.facs.org/about-acs/statements/or-attire/>. Published February 27, 2018. Accessed March 28, 2023.
 276. Moehring RW, Anderson DJ. “But my patients are different!”: risk adjustment in 2012 and beyond. *Infect Control Hosp Epidemiol* 2011;32:987–989.
 277. Culver DH, Horan TC, Gaynes RP, *et al*. Surgical wound infection rates by wound class, operative procedure, and patient risk index, National Nosocomial Infections Surveillance System. *Am J Med* 1991;91:152S–157S.
 278. Malpiedi PJ, Peterson KD, Soe MM, Edwards JR, Scott II RD. *National and state healthcare-associated infection standardized infection ratio report*. Centers for Disease Control and Prevention website. http://www.cdc.gov/hai/pdfs/SIR/SIR-Report_02_07_2013.pdf. Published May 13, 2013. Accessed March 28, 2023.
 279. Mu Y, Edwards JR, Horan TC, Berrios-Torres SI, Fridkin SK. Improving risk-adjusted measures of surgical site infection for the national healthcare safety network. *Infect Control Hosp Epidemiol* 2011;32:970–986.
 280. Gaynes RP, Solomon S. Improving hospital-acquired infection rates: the CDC experience. *Jt Comm J Qual Improv* 1996;22:457–467.
 281. Consensus paper on the surveillance of surgical wound infections: the Society for Hospital Epidemiology of America, the Association for Practitioners in Infection Control, the Centers for Disease Control, and the Surgical Infection Society. *Infect Control Hosp Epidemiol* 1992;13:599–605.
 282. Berrios-Torres SI, Mu Y, Edwards JR, Horan TC, Fridkin SK. Improved risk adjustment in public reporting: coronary artery bypass graft surgical site infections. *Infect Control Hosp Epidemiol* 2012;33:463–469.
 283. Calderwood MS, Kleinman K, Soumerai SB, *et al*. Impact of Medicare’s payment policy on mediastinitis following coronary artery bypass graft surgery in US hospitals. *Infect Control Hosp Epidemiol* 2014;35:144–151.
 284. Masnick M, Morgan DJ, Sorkin JD, *et al*. Lack of patient understanding of hospital-acquired infection data published on the Centers for Medicare and Medicaid Services hospital compare website. *Infect Control Hosp Epidemiol* 2016;37:182–187.
 285. Wong ES, Rupp ME, Mermel L, *et al*. Public disclosure of healthcare-associated infections: the role of the Society for Healthcare Epidemiology of America. *Infect Control Hosp Epidemiol* 2005;26:210–212.
 286. McKibben L, Horan T, Tokars JJ, *et al*. Guidance on public reporting of healthcare-associated infections: recommendations of the Healthcare Infection Control Practices Advisory Committee. *Am J Infect Control* 2005;33:217–226.
 287. Talbot TR, Bratzler DW, Carrico RM, *et al*. Public reporting of healthcare-associated surveillance data: recommendations from the healthcare infection control practices advisory committee. *Ann Intern Med* 2013;159:631–635.
 288. National voluntary consensus standards for the reporting of healthcare-associated infections data. National Quality Forum website. http://www.qualityforum.org/Publications/2008/03/National_Voluntary_Consensus_Standards_for_the_Reporting_of_Healthcare-Associated_Infection_Data.aspx. Published January 6, 2013. Accessed March 28, 2023.
 289. Centers for Medicare & Medicaid Services. Medicare program; hospital inpatient prospective payment systems for acute care hospitals and the long-term care hospital prospective payment system and FY 2012 rates; hospitals’ FTE resident caps for graduate medical education payment. Final rules. *Fed Register* 2011;76:51476–51846.
 290. Anthony T, Murray BW, Sum-Ping JT, *et al*. Evaluating an evidence-based bundle for preventing surgical site infection: a randomized trial. *Arch Surg* 2011;146:263–269.
 291. Centers for Medicare & Medicaid Services. Operational guidance for reporting surgical site infection (SSI) data to CDC NHSN for the purpose of fulfilling CMS Hospital Inpatient Quality Reporting (IQR) program requirements. Centers for Disease Control and Prevention website. <https://www.cdc.gov/nhsn/pdfs/cms/ssi/Final-ACH-SSI-Guidance.pdf>. Published November 2019. Accessed March 28, 2023.
 292. Quality and patient safety resources. Agency for Healthcare Research and Quality website. <https://www.ahrq.gov/patient-safety/resources/index.html#projects>. Updated December 2022. Accessed March 28, 2023.
 293. Harris JA, Sammarco AG, Swenson CW, *et al*. Are perioperative bundles associated with reduced postoperative morbidity in women undergoing benign hysterectomy? Retrospective cohort analysis of 16,286 cases in Michigan. *Am J Obstet Gynecol* 2017;216:502.e1–e11.

294. Young H, Knepper B, Vigil C, Miller A, Carey JC, Price CS. Sustained reduction in surgical site infection after abdominal hysterectomy. *Surg Infect (Larchmt)* 2013;14:460–463.
295. Glotzbecker M, Troy M, Miller P, Berry J, Cohen L, Gryzwna A, et al. Implementing a multidisciplinary clinical pathway can reduce the deep surgical site infection rate after posterior spinal fusion in high-risk patients. *Spine Deform* 2019;7:33–39.
296. Gorgun E, Rencuzogullari A, Ozben V, et al. An effective bundled approach reduces surgical site infections in a high-outlier colorectal unit. *Dis Colon Rectum* 2018;61:89–98.
297. Kaplan HC, Brady PW, Dritz MC, et al. The influence of context on quality improvement success in health care: a systematic review of the literature. *Milbank Q* 2010;88:500–559.
298. Tomoia-Cotisel A, Scammon DL, Waitzman NJ, et al. Context matters: the experience of 14 research teams in systematically reporting contextual factors important for practice change. *Ann Fam Med* 2013;11 suppl 1: S115–123.
299. Hsu CD, Cohn I, Caban R. Reduction and sustainability of cesarean section surgical site infection: an evidence-based, innovative, and multidisciplinary quality improvement intervention bundle program. *Am J Infect Control* 2016;44:1315–1320.
300. Hewitt DB, Tannouri SS, Burkhart RA, et al. Reducing colorectal surgical site infections: a novel, resident-driven, quality initiative. *Am J Surg* 2017;213:36–42.
301. Lippitt MH, Fairbairn MG, Matsuno R, et al. Outcomes associated with a five-point surgical site infection prevention bundle in women undergoing surgery for ovarian cancer. *Obstet Gynecol* 2017;130:756–764.
302. Parizh D, Ascher E, Raza Rizvi SA, Hingorani A, Amaturo M, Johnson E. Quality improvement initiative: preventative surgical site infection protocol in vascular surgery. *Vascular* 2018;26:47–53.
303. Wright JG. Reducing surgical site infections in a children's hospital: the fuzzy elements of change. *J Clin Outcomes Manage* 2016;23:157–163.
304. Forrester JA, Koritsanszky LA, Amenu D, et al. Developing process maps as a tool for a surgical infection prevention quality improvement initiative in resource-constrained settings. *J Am Coll Surg* 2018;226:1103–1116.
305. Fisher JC, Godfried DH, Lighter-Fisher J, et al. A novel approach to leveraging electronic health record data to enhance pediatric surgical quality improvement bundle process compliance. *J Pediatr Surg* 2016;51:1030–1033.
306. Schwann NM, Bretz KA, Eid S, et al. Point-of-care electronic prompts: an effective means of increasing compliance, demonstrating quality, and improving outcome. *Anesth Analg* 2011;113:869–876.
307. Andiman SE, Xu X, Boyce JM, et al. Decreased surgical site infection rate in hysterectomy: effect of a gynecology-specific bundle. *Obstet Gynecol* 2018;131:991–999.
308. Agarwal N, Agarwal P, Querry A, et al. Implementation of an infection prevention bundle and increased physician awareness improves surgical outcomes and reduces costs associated with spine surgery. *J Neurosurg Spine* 2018;29:108–114.
309. Cassir N, De La Rosa S, Melot A, et al. Risk factors for surgical site infections after neurosurgery: a focus on the postoperative period. *Am J Infect Control* 2015;43:1288–1291.
310. Hoang SC, Klipfel AA, Roth LA, Vrees M, Schechter S, Shah N. Colon and rectal surgery surgical site infection reduction bundle: to improve is to change. *Am J Surg* 2019;217:40–45.
311. Ceppa EP, Pitt HA, House MG, et al. Reducing surgical site infections in hepatopancreatobiliary surgery. *HPB (Oxford)* 2013;15:384–391.
312. Abbas M, de Kraker MEA, Aghayev E, et al. Impact of participation in a surgical site infection surveillance network: results from a large international cohort study. *J Hosp Infect* 2019;102:267–276.
313. Waits SA, Fritze D, Banerjee M, et al. Developing an argument for bundled interventions to reduce surgical site infection in colorectal surgery. *Surgery* 2014;155:602–606.
314. Lyren A, Brilli RJ, Zieker K, Marino M, Muething S, Sharek PJ. Children's hospitals' solutions for patient safety collaborative impact on hospital-acquired harm. *Pediatrics* 2017;140.
315. Benlice CGE. Using NSQIP data for quality improvement: the Cleveland Clinic SSI experience. *Semin Colon Rectal Surg* 2016;27:74–82.
316. Lin DM, Carson KA, Lubomski LH, Wick EC, Pham JC. Statewide collaborative to reduce surgical site infections: results of the hawaii surgical unit-based safety program. *J Am Coll Surg* 2018;227:189–197.
317. Willis ZI, Duggan EM, Bucher BT, et al. Effect of a clinical practice guideline for pediatric complicated appendicitis. *JAMA Surg* 2016;151: e160194.
318. Riley MM, Suda D, Tabsh K, Flood A, Pegues DA. Reduction of surgical site infections in low transverse cesarean section at a university hospital. *Am J Infect Control* 2012;40:820–825.
319. Wick EC, Hobson DB, Bennett JL, et al. Implementation of a surgical comprehensive unit-based safety program to reduce surgical site infections. *J Am Coll Surg* 2012;215:193–200.
320. Zhou L, Ma J, Gao J, Chen S, Bao J. Optimizing prophylactic antibiotic practice for cardiothoracic surgery by pharmacists' effects. *Medicine (Baltimore)* 2016;95:e2753.
321. Bogun M. Positive influence of weekly diabetes workshops for healthcare providers managing patients recovering after coronary artery bypass graft surgery (CABG): its potential role in reducing the surgical site infections. *Diabetes* 2017;66 suppl 1:A174.
322. Johnson MP, Kim SJ, Langstraat CL, et al. Using bundled interventions to reduce surgical site infection after major gynecologic cancer surgery. *Obstet Gynecol* 2016;127:1135–1144.
323. Kapadia BH, Cherian JJ, Issa K, Jagannathan S, Daley JA, Mont MA. Patient compliance with preoperative disinfection protocols for lower extremity total joint arthroplasty. *Surg Technol Int* 2015;26:351–354.
324. Schaffzin JK, Mangeot C, Sucharew H, Beck AF, Sturm PF. Factors affecting adherence to a preoperative surgical site infection prevention protocol. *Infect Control Hosp Epidemiol* 2016;37:728–730.
325. Eskildsen SM, Moskal PT, Laux J, Del Gaizo DJ. The effect of a door alarm on operating room traffic during total joint arthroplasty. *Orthopedics* 2017;40:e1081–e1085.
326. Ehrenfeld JM, Wanderer JP, Terekhov M, Rothman BS, Sandberg WS. A perioperative systems design to improve intraoperative glucose monitoring is associated with a reduction in surgical site infections in a diabetic patient population. *Anesthesiology* 2017;126:431–440.
327. O'Sullivan CT, Rogers WK, Ackman M, Goto M, Hoff BM. Implementation of a multifaceted program to sustainably improve appropriate intraoperative antibiotic redosing. *Am J Infect Control* 2019;47:74–77.
328. Koek MBG, Hopmans TEM, Soetens LC, et al. Adhering to a national surgical care bundle reduces the risk of surgical site infections. *PLoS One* 2017;12:e0184200.
329. Roth B, Neuenschwander R, Brill F, et al. Effect of antiseptic irrigation on infection rates of traumatic soft tissue wounds: a longitudinal cohort study. *J Wound Care* 2017;26:79–87.
330. Wathen C, Kshetry VR, Krishnaney A, et al. The association between operating room personnel and turnover with surgical site infection in more than 12,000 neurosurgical cases. *Neurosurgery* 2016; 79:889–894.
331. Grant MC, Hanna A, Benson A, et al. Dedicated operating room teams and clinical outcomes in an enhanced recovery after surgery pathway for colorectal surgery. *J Am Coll Surg* 2018;226:267–276.
332. Lapanluoma M, Rahi M, Takala R, Loyttyniemi E, Ikonen TS. Analysis of neurosurgical reoperations: use of a surgical checklist and reduction of infection-related and preventable complication-related reoperations. *J Neurosurg* 2015;123:145–152.
333. Tvedt C, Sjetne IS, Helgeland J, Lower HL, Bukholm G. Nurses' reports of staffing adequacy and surgical site infections: a cross-sectional multicentre study. *Int J Nurs Stud* 2017;75:58–64.
334. Pop-Vicas AE, Keating JA, Heise C, Carayon P, Safdar N. Gaining momentum in colorectal surgical site infection reduction through a human factors engineering approach. *Infect Control Hosp Epidemiol* 2021;42:893–895.
335. Wadhwa A, Kabon B, Fleischmann E, Kurz A, Sessler DI. Supplemental postoperative oxygen does not reduce surgical site infection and major healing-related complications from bariatric surgery in morbidly obese patients: a randomized, blinded trial. *Anesth Analg* 2014;119:357–365.

336. Thompson KM, Oldenburg WA, Deschamps C, Rupp WC, Smith CD. Chasing zero: the drive to eliminate surgical site infections. *Ann Surg* 2011;254:430–436.
337. Pronovost PJ, Berenholtz SM, Needham DM. Translating evidence into practice: a model for large-scale knowledge translation. *BMJ* 2008;337:a1714.
338. Hranjec T, Swenson BR, Sawyer RG. Surgical site infection prevention: how we do it. *Surg Infect (Larchmt)* 2010;11:289–294.
339. Guyatt GH, Oxman AD, Vist GE, *et al*. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008;336:924–926.
340. GRADE 2013. Canadian Task Force on Preventive Health Care website. <http://canadiantaskforce.ca/methods/grade/>. Published December 31, 2013. Accessed March 28, 2023.
341. Kaye KS, Schmit K, Pieper C, *et al*. The effect of increasing age on the risk of surgical site infection. *J Infect Dis* 2005;191:1056–1062.
342. Pessaux P, Msika S, Atalla D, *et al*. Risk factors for postoperative infectious complications in noncolorectal abdominal surgery: a multivariate analysis based on a prospective multicenter study of 4,718 patients. *Arch Surg* 2003;138:314–324.
343. Raymond DP, Pelletier SJ, Crabtree TD, Schulman AM, Pruett TL, Sawyer RG. Surgical infection and the aging population. *Am Surg* 2001;67:827–832.
344. Faraday N, Rock P, Lin EE, *et al*. Past history of skin infection and risk of surgical site infection after elective surgery. *Ann Surg* 2013;257:150–154.
345. de Vries FEE, Atema JJ, Lapid O, Obdeijn MC, Boormeester MA. Closed incision prophylactic negative pressure wound therapy in patients undergoing major complex abdominal wall repair. *Hernia* 2017;21:583–589.
346. Forse RA, Karam B, MacLean LD, Christou NV. Antibiotic prophylaxis for surgery in morbidly obese patients. *Surgery* 1989;106:750–756.
347. Hawn MT, Houston TK, Campagna EJ, *et al*. The attributable risk of smoking on surgical complications. *Ann Surg* 2011;254:914–920.
348. Moller AM, Pedersen T, Villebro N, Munksgaard A. Effect of smoking on early complications after elective orthopaedic surgery. *J Bone Joint Surg Br* 2003;85:178–181.
349. Moller AM, Villebro N, Pedersen T, Tonnesen H. Effect of preoperative smoking intervention on postoperative complications: a randomised clinical trial. *Lancet* 2002;359:114–117.
350. Sharma A, Deeb AP, Iannuzzi JC, Rickles AS, Monson JR, Fleming FJ. Tobacco smoking and postoperative outcomes after colorectal surgery. *Ann Surg* 2013;258:296–300.
351. Theadom A, Croypley M. Effects of preoperative smoking cessation on the incidence and risk of intraoperative and postoperative complications in adult smokers: a systematic review. *Tob Control* 2006;15:352–358.
352. Hennessey DB, Burke JP, Ni-Dhonochu T, Shields C, Winter DC, Mealy K. Preoperative hypoalbuminemia is an independent risk factor for the development of surgical site infection following gastrointestinal surgery: a multi-institutional study. *Ann Surg* 2010;252:325–329.
353. Nicolle LE, Gupta K, Bradley SF, *et al*. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. *Clin Infect Dis* 2019;68:e83–e110.
354. Boyce JM, Pittet D, Healthcare Infection Control Practices Advisory Committee. Guideline for hand hygiene in healthcare settings: recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. *MMWR Recomm Rep* 2002;51(RR-16):1–45.
355. Ford CD, VanMoorleghem G, Menlove RL. Blood transfusions and postoperative wound infection. *Surgery* 1993;113:603–607.
356. Horvath KA, Acker MA, Chang H, *et al*. Blood transfusion and infection after cardiac surgery. *Ann Thorac Surg* 2013;95:2194–2201.
357. Olsen MA, Lock-Buckley P, Hopkins D, Polish LB, Sundt TM, Fraser VJ. The risk factors for deep and superficial chest surgical-site infections after coronary artery bypass graft surgery are different. *J Thorac Cardiovasc Surg* 2002;124:136–145.
358. Alexander JW, Solomkin JS, Edwards MJ. Updated recommendations for control of surgical site infections. *Ann Surg* 2011;253:1082–1093.
359. Guidelines—ANSI/ASHRAE/ASHE standard 170: ventilation of healthcare facilities, 2010. Facility Guidelines Institute website. <http://www.fgiguideines.org/guideines2010.php>. Published February 2, 2013. Accessed March 28, 2023.
360. Change in terminology and update of survey and certification (S&C) memorandum 09-55 regarding immediate use steam sterilization (IUSS) in surgical settings. Centers for Medicare and Medicaid Services website. <https://www.cms.gov/Medicare/Provider-Enrollment-and-Certification/Survey-Certification/GenInfo/Policy-and-Memos-to-States-and-Regions-Items/Survey-and-Cert-Letter-14-44>. Published 2014. Accessed March 2023.
361. Condition of participation: Infection prevention and control and antibiotic stewardship programs. §482.42. Centers for Medicare and Medicaid Services website. <https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-G/part-482/subpart-C/section-482.42>. Published 2021. Accessed March 2023.
362. Horan TC, Gaynes RP, Martone WJ, Jarvis WR, Emori TG. CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections. *Infect Control Hosp Epidemiol* 1992;13:606–608.